Delaware |
2300 |
46-2005653 | ||
| (State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
| Marc D. Jaffe Ian D. Schuman Alison A. Haggerty Latham & Watkins LLP 1271 Avenue of the Americas New York, New York 10020 (212) 906-1200 |
Jeffrey D. Lawrence Chief Financial Officer FIGS, Inc. 2834 Colorado Avenue, Suite 100 Santa Monica, California 90404 (424) 500-8209 |
Dave Peinsipp Kristin VanderPas Charles S. Kim Cooley LLP 101 California Street, 5th Floor San Francisco, California 94111 (415) 693-2000 |
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
| Emerging growth company |
| | ||||||||
| Title of Each Class of Securities to be Registered |
Amount to be Registered (1) |
Proposed Maximum Offering Price Per Share (2) |
Proposed Maximum Aggregate Offering Price (2) |
Amount of Registration Fee | ||||
| Class A common stock, par value $0.0001 per share |
10,150,708 |
$42.27 |
$429,070,427.16 |
$46,811.58 | ||||
| | ||||||||
| | ||||||||
(1) |
Includes 1,324,005 shares of Class A common stock that the underwriters have the option to purchase from the selling stockholders. |
(2) |
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act of 1933, as amended. The price per share and aggregate offering price are based on the average of the high and low prices of the Registrant’s Class A common stock on September 10, 2021, as reported on the New York Stock Exchange. |

CLASS A COMMON STOCK |
8,826,703 SHARES |
Per Share |
Total |
|||||||
| Public offering price |
$ |
$ |
||||||
| Underwriting discount and commissions (1) |
$ |
$ |
||||||
| Proceeds, before expenses, to the selling stockholders |
$ |
$ |
||||||
GOLDMAN SACHS & CO. LLC |
MORGAN STANLEY |
BARCLAYS |
CREDIT SUISSE |
BofA SECURITIES |
COWEN |
GUGGENHEIM SECURITIES |
KEYBANC CAPITAL MARKETS |
OPPENHEIMER & CO. |
PIPER SANDLER |
TELSEY ADVISORY GROUP |
ACADEMY SECURITIES |
R. SEELAUS & CO., LLC |
RAMIREZ & CO., INC. |
SIEBERT WILLIAMS SHANK |
Page |
||||
1 |
||||
16 |
||||
54 |
||||
56 |
||||
57 |
||||
58 |
||||
59 |
||||
62 |
||||
84 |
||||
107 |
||||
115 |
||||
121 |
||||
123 |
||||
125 |
||||
133 |
||||
136 |
||||
140 |
||||
147 |
||||
147 |
||||
147 |
||||
F-1 |
||||
| • | Expanded our community of active customers by 118% from 0.6 million to approximately 1.3 million; |
| • | Increased net revenues from $110.5 million to $263.1 million, representing 138% year-over-year growth; |
| • | Increased gross margin by 50 basis points from 71.8% to 72.3%; |
| • | Improved net operating (loss) income from $(0.3) million to $57.9 million; |
| • | Increased Adjusted EBITDA from $1.7 million to $69.1 million, representing an Adjusted EBITDA margin of 26.3% in 2020; |
| • | Increased cash flow from operations from $6.5 million to $21.7 million; and |
| • | Increased free cash flow from $1.8 million to $19.5 million. |
| • | Expanded our community of active customers by 79.2% from approximately 0.9 million to approximately 1.6 million; |
| • | Increased net revenues from $96.1 million to $188.2 million, representing 95.8% year-over-year growth; |
| • | Increased gross margin by 0.2 percentage points from 72.3% to 72.5%; |
| • | Net operating income (loss) decreased from $20.6 million to $(16.0) million; |
| • | Increased Adjusted EBITDA from $21.9 million to $51.1 million, representing an Adjusted EBITDA margin of 27.2% in 2021; |
| • | Increased cash flow from operations from $24.3 million to $32.7 million; and |
| • | Increased free cash flow from $23.2 million to $31.7 million. |
| * | NM = Not Meaningful |
| • | Commoditized Products. ill-fitting, uncomfortable, baggy, boxy and lacking in design and functionality, with minimal focus on fabric technology or performance. |
| • | Brand Obscurity. |
| • | Antiquated Distribution. brick-and-mortar |
| • | Channel Conflict. |
| • | Customer Separation. |
| • | Challenged Margins. |
| • | Resilient Industry with Favorable Long-Term Trends. non-discretionary, replenishment nature of its products and the secular growth of the healthcare sector. |
| • | Increased Demand for Healthcare Professionals. |
| • | Acceleration of eCommerce. |
| • | Attraction to Purpose-Driven Brands. |
| • | Magnified Importance of Technically Advanced Healthcare Apparel. COVID-19 pandemic has magnified the indispensability of healthcare professionals. Due to the pandemic, more healthcare professionals are choosing to wear medical apparel, and a greater number of hospitals, medical offices and clinics are requiring staff to wear scrubs and other medical apparel. While we demonstrated consistent and significant growth prior to 2020, we believe the pandemic has accelerated awareness of the FIGS brand and a shift in purchasing decisions that will continue to drive future growth. |
| • | Our recent rapid growth may not be sustainable or indicative of future growth, and we expect our growth rate to ultimately slow over time. |
| • | If we fail to manage our growth effectively, our business, financial condition and results of operations may be adversely affected. |
| • | We have only recently achieved profitability and may not maintain profitability in the future. |
| • | Our success depends on our ability to maintain the value and reputation of our brand. |
| • | If we fail to attract new customers, retain existing customers, or fail to maintain or increase sales to those customers, our business, financial condition, results of operations and growth prospects will be harmed. |
| • | If our marketing efforts are not successful, our business, financial condition and results of operations could be harmed. |
| • | Our business depends on our ability to maintain a strong community of engaged customers and Ambassadors, including through the use of social media. We may not be able to maintain and enhance our brand if we experience negative publicity related to our marketing efforts or use of social media, fail to maintain and grow our network of Ambassadors or otherwise fail to meet our customers’ expectations. |
| • | If we do not continue to successfully develop and introduce new, innovative and updated products, we may not be able to maintain or increase our sales and profitability. |
| • | The market for healthcare apparel is highly competitive. |
| • | Our future success depends on the continuing efforts of our key employees and our ability to attract and retain highly skilled personnel and senior management. |
| • | We plan to expand into additional international markets, which will expose us to new risks. |
| • | Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements, could adversely affect our business, financial condition and results of operations. |
| • | If we are unable to accurately forecast customer demand, manage our inventory and plan for future expenses, our results of operations could be adversely affected. |
| • | Our business may be subject to uncertainty as a result of the COVID-19 pandemic. |
| • | Our reliance on a limited number of third-party suppliers to provide materials for and produce our products could cause problems in our supply chain and subject us to additional risks. |
| • | The dual-class structure of our common stock and voting agreement among us and the Class B stockholders has the effect of concentrating control with our co-founders and co-Chief Executive Officers, and Tulco, LLC. |
| • | We are a “controlled company” within the meaning of the rules of the New York Stock Exchange and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. You do not have the same protections afforded to stockholders of companies that are subject to such requirements. |
| • | the option to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; |
| • | not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002; |
| • | reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and |
| • | exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. |
| Class A common stock offered by the selling stockholders |
8,826,703 shares |
| Option to purchase additional shares of Class A common stock offered by the selling stockholders |
The selling stockholders have granted the underwriters a 30-day option to purchase up to 1,324,005 additional shares of our Class A common stock at the public offering price, less the underwriting discounts and commissions. |
| Class A common stock to be outstanding after this offering |
151,021,138 shares |
| Class B common stock to be outstanding after this offering |
12,302,907 shares |
| Total common stock to be outstanding after this offering |
163,324,045 shares |
| Use of Proceeds |
The selling stockholders will receive all net proceeds from the sale of the shares of Class A common stock to be sold in this offering, and we will not receive any of these proceeds. See the section titled “Use of Proceeds” for additional information. |
| Voting Rights |
Shares of our Class A common stock are entitled to one vote per share. Shares of our Class B common stock are entitled to 20 votes per share. |
| Holders of our Class A common stock and Class B common stock generally vote together as a single class, unless otherwise required by law or our amended and restated certificate of incorporation. Each share of our Class B common stock is convertible into one share of our Class A common stock at any time and will convert automatically upon certain transfers and in certain other circumstances as described in our amended and restated certificate of incorporation. See “—Our Dual-Class Capital Structure” above. All outstanding shares of our Class B common stock are held by our co-founders and co-Chief Executive Officers, Heather Hasson and Trina Spear, and Tulco, LLC, our majority stockholder. Immediately following the completion of this offering, these holders will represent approximately 80.1% of the voting power of our outstanding capital stock, assuming no exercise of the underwriters’ option to purchase additional shares. These Class B stockholders have the ability to control the outcome of matters submitted to our stockholders for approval, including the election of our directors and the approval of any change of control transaction. In addition, we and the Class B stockholders have entered into a voting agreement with respect to the election of directors. See the sections titled “Principal and Selling Stockholders” and “Description of Capital Stock” for additional information. |
| Controlled Company |
We are a “controlled company” within the meaning of the corporate governance rules of the NYSE. |
| Risk Factors |
See the section titled “Risk Factors” and other information included in this prospectus for a discussion of some of the factors you should consider before deciding to purchase shares of our Class A common stock. |
| NYSE Symbol |
“FIGS” |
| • | 39,718,610 shares of our Class A common stock issuable upon the exercise of outstanding stock options under our Amended 2016 Equity Incentive Plan, or our 2016 Plan, as of August 31, 2021, at a weighted-average exercise price of $3.74 per share, including 33,387,120 shares underlying stock option awards that are subject to the Equity Award Exchange Agreement (defined below); and |
| • | 3,381,520 shares of our Class A common stock issuable upon the vesting and settlement of outstanding restricted stock units, or RSUs, under our 2016 Plan as of August 31, 2021, all of which are subject to the Equity Award Exchange Agreement. |
| • | 13,157,003 shares of our Class A common stock reserved for future issuance under our 2021 Equity Incentive Plan, or our 2021 Plan; and |
| • | 1,605,647 shares of our Class A common stock reserved for issuance under our 2021 Employee Stock Purchase Plan, or our ESPP. |
| • | no exercise of outstanding stock options or vesting and settlement of outstanding RSUs referred to above after August 31, 2021, other than the exercise of stock options in connection with the sale of shares in this offering (see “Principal and Selling Stockholders” for more information); and |
| • | no exercise by the underwriters of their option to purchase up to an additional 1,324,005 shares of our Class A common stock from the selling stockholders in this offering. |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||
| Statements of Operations Data: |
||||||||||||||||
| Net revenues |
$ | 110,494 | $ | 263,112 | $ | 96,110 | $ | 188,196 | ||||||||
| Cost of goods sold |
31,158 | 72,888 | 26,578 | 51,683 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
79,336 | 190,224 | 69,532 | 136,513 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Selling |
24,840 | 51,896 | 19,644 | 36,337 | ||||||||||||
| Marketing |
33,193 | 38,852 | 16,142 | 26,327 | ||||||||||||
| General and administrative (1) |
21,650 | 41,536 | 13,150 | 89,850 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
79,683 | 132,284 | 48,936 | 152,514 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net (loss) income from operations |
(347 | ) | 57,940 | 20,596 | (16,001 | ) | ||||||||||
| Other income (loss), net |
459 | 136 | 116 | (69 | ) | |||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) before income tax provision |
112 | 58,076 | 20,712 | (16,070 | ) | |||||||||||
| Provision for income taxes |
— | 8,318 | 2,403 | 13,036 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | 112 | $ | 49,758 | $ | 18,309 | $ | (29,106 | ) | |||||||
| |
|
|
|
|
|
|
|
|||||||||
| Basic earnings (loss) per share (2) |
$ | — | $ | 0.32 | $ | 0.12 | $ | (0.19) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Diluted earnings (loss) per share (2) |
$ | — | $ | 0.30 | $ | 0.12 | $ | (0.19) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding - basic (2) |
153,052,983 |
153,327,308 |
153,052,983 |
155,725,959 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding - diluted (2) |
153,624,013 |
163,331,348 |
153,661,856 |
155,725,959 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| (1) | Includes stock-based compensation expense of $0.2 million and $8.7 million for the years ended December 31, 2019 and 2020, respectively, and $0.3 million and $61.0 million for the six months ended June 30, 2020 and 2021, respectively. |
| (2) | See Note 13 to our audited financial statements and Note 11 to our unaudited interim financial statements included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted earnings per share and the weighted-average number of shares used in the computation of the per share amounts. |
As of December 31, |
As of June 30, |
|||||||||||
2019 |
2020 |
2021 |
||||||||||
(in thousands) |
||||||||||||
| Balance Sheet Data: |
||||||||||||
| Cash and cash equivalents |
$ | 38,353 | $ | 58,133 | $ | 163,968 | ||||||
| Total assets |
62,598 |
133,855 |
254,254 |
|||||||||
| Total liabilities |
23,784 |
36,178 |
50,539 |
|||||||||
| Total stockholders’ equity |
38,814 |
97,677 |
203,715 |
|||||||||
| • | the need to adapt and localize products for specific countries to account for, among other things, different cultural tastes, size and fit preferences or regulatory requirements; |
| • | difficulty establishing and managing international operations and the increased operations, travel, infrastructure, including establishment of local delivery service and customer service operations, and legal compliance costs associated with locations in different countries or regions; |
| • | increased shipping times to and from international markets; |
| • | the need to vary pricing and margins to effectively compete in international markets; |
| • | increased competition from local providers of similar products; |
| • | the ability to protect and enforce intellectual property rights abroad; |
| • | the need to offer customer support in various languages; |
| • | difficulties in understanding and complying with local laws, regulations and customs in other jurisdictions; |
| • | compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, or FCPA, and the U.K. Bribery Act 2010, or U.K. Bribery Act, by us, our employees and our business partners; |
| • | complexity and other risks associated with current and future legal requirements in other countries, including legal requirements related to medical apparel, customer advertising protection, customer product safety and data privacy frameworks, such as the EU General Data Protection Regulation 2016/679, or GDPR; |
| • | varying business practices and customs related to the sale of medical apparel; |
| • | varying levels of internet technology adoption and infrastructure, and increased or varying network and hosting service provider costs; |
| • | tariffs and other non-tariff barriers, such as quotas and local content rules, as well as tax consequences; |
| • | fluctuations in currency exchange rates and the requirements of currency control regulations, which might restrict or prohibit conversion of other currencies into U.S. dollars; and |
| • | political or social unrest or economic instability in a specific country or region in which we operate, including, for example, the effects of “Brexit,” which could have an adverse impact on our operations in that location. |
| • | the imposition of new laws and regulations, including those relating to labor conditions, quality and safety standards, imports, duties, taxes and other charges on imports, as well as trade restrictions and restrictions on currency exchange or the transfer of funds; |
| • | political unrest, terrorism, labor disputes and economic instability resulting in the disruption of trade from foreign countries in which our products are manufactured; |
| • | reduced protection for intellectual property rights, including trademark protection, in some countries, particularly in China; |
| • | disruptions or delays in shipments whether due to port congestion, labor disputes, product regulations and/or inspections or other factors, natural disasters or health pandemics, or other transportation disruptions; and |
| • | the impact of health conditions, including the ongoing COVID-19 pandemic, and related government and private sector responsive actions, and other changes in local economic conditions in countries where our manufacturers, suppliers or customers are located. |
| • | problems integrating the acquired business, facilities, technologies or products, including issues maintaining uniform standards, procedures, controls, policies and culture; |
| • | unanticipated costs associated with acquisitions, investments or strategic alliances; |
| • | diversion of management’s attention from our existing business; |
| • | adverse effects on existing business relationships with suppliers, outsourced manufacturing partners and other third parties; |
| • | risks associated with entering new markets in which we may have limited or no experience; |
| • | potential loss of key employees of acquired businesses; and |
| • | increased legal and accounting compliance costs. |
| • | actual or anticipated fluctuations in our financial condition and results of operations; |
| • | the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections; |
| • | failure of securities analysts to initiate or maintain coverage of our company, changes in financial estimates or ratings by any securities analysts who follow our company or our failure to meet these estimates or the expectations of investors; |
| • | announcements by us or our competitors of significant technical innovations, acquisitions, strategic partnerships, joint ventures, results of operations or capital commitments; |
| • | changes in stock market valuations and operating performance of other healthcare and technology companies generally, or those in our industry in particular; |
| • | price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole; |
| • | changes in our board of directors or management; |
| • | sales of large blocks of our Class A common stock, including sales by Tulco, LLC, our co-founders and co-Chief Executive Officers or our other executive officers and directors; |
| • | lawsuits threatened or filed against us; |
| • | anticipated or actual changes in laws, regulations or government policies applicable to our business; |
| • | changes in our capital structure, such as future issuances of debt or equity securities; |
| • | short sales, hedging and other derivative transactions involving our capital stock; |
| • | general economic conditions in the United States; |
| • | other events or factors, including those resulting from war, pandemics (including COVID-19), incidents of terrorism or responses to these events; and |
| • | the other factors described in the sections of this prospectus titled “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” |
| • | the requirement that a majority of the board of directors consist of independent directors; |
| • | the requirement that our nominating and corporate governance committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; |
| • | the requirement that our compensation committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
| • | the requirement for an annual performance evaluation of our governance and compensation committees. |
| • | provide for a dual-class common stock structure in which holders of our Class B common stock may have the ability to control the outcome of matters requiring stockholder approval, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, even if they own significantly less than a majority of the outstanding shares of our common stock; |
| • | restrict the forum for certain litigation against us to Delaware or the federal courts, as applicable; |
| • | our board of directors has the exclusive right to expand the size of our board of directors and to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; |
| • | our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; |
| • | our stockholders may act by written consent until such time as holders of our Class B common stock beneficially own less than a majority of the voting power, at which time our stockholders will no longer be able to act by written consent and instead must take action at an annual or special meeting of our stockholders; |
| • | a special meeting of stockholders may be called only by the chair of the board of directors, a chief executive officer, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; |
| • | our amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; |
| • | our board of directors may alter our amended and restated bylaws without obtaining stockholder approval; |
| • | the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; |
| • | stockholders must provide advance notice and additional disclosures in order to nominate individuals for election to the board of directors or to propose matters that can be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies |
| to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of our company; and |
| • | our board of directors is authorized to issue shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer. |
| • | fluctuations in product mix; |
| • | our ability to effectively launch and manage new products; |
| • | fluctuations in the levels or quality of inventory; |
| • | fluctuations in capacity as we expand our operations; |
| • | our success in engaging existing customers and attracting new customers; |
| • | the amount and timing of our operating expenses; |
| • | the timing and success of new products launches; |
| • | the impact of competitive developments and our response to those developments; |
| • | our ability to manage our existing business and future growth; and |
| • | economic and market conditions, particularly those affecting our industry. |
| • | our future financial performance, including our expectations regarding our net revenues, cost of goods sold, gross profit, operating expenses and other operating results, as well as our ability to achieve and maintain future profitability; |
| • | our business plan, beliefs and objectives for future operations; |
| • | our ability to continue to experience and effectively manage our rapid growth; |
| • | our market opportunity; |
| • | our international expansion plans; |
| • | our ability to promote our brand; |
| • | our ability to attract new customers and to retain and drive repeat purchases from our existing customers; |
| • | our ability to develop new products and bring them to market in a timely manner; |
| • | our expectations concerning relationships with third parties; |
| • | our ability to maintain, protect and enhance our intellectual property; |
| • | the effects of increased competition in our markets and our ability to compete effectively; and |
| • | economic and industry trends, projected growth or trend analysis. |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||
| Statements of Operations Data: |
||||||||||||||||
| Net revenues |
$ | 110,494 | $ | 263,112 | $ | 96,110 | $ | 188,196 | ||||||||
| Cost of goods sold |
31,158 | 72,888 | 26,578 | 51,683 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
79,336 | 190,224 | 69,532 | 136,513 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Selling |
24,840 |
51,896 |
19,644 |
36,337 |
||||||||||||
| Marketing |
33,193 | 38,852 | 16,142 | 26,327 | ||||||||||||
| General and administrative (1) |
21,650 |
41,536 |
13,150 |
89,850 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
79,683 |
132,284 |
48,936 |
152,514 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net (loss) income from operations |
(347 |
) |
57,940 |
20,596 |
(16,001 |
) | ||||||||||
| Other income (loss), net |
459 |
136 |
116 |
(69 |
) | |||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) before income tax provision |
112 |
58,076 |
20,712 |
(16,070 |
) | |||||||||||
| Provision for income taxes |
— |
8,318 |
2,403 |
13,036 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | 112 | $ | 49,758 | $ | 18,309 | $ | (29,106 | ) | |||||||
| |
|
|
|
|
|
|
|
|||||||||
| Basic earnings (loss) per share |
$ | — | $ | 0.32 | $ | 0.12 | $ | (0.19 | ) | |||||||
| |
|
|
|
|
|
|
|
|||||||||
| Diluted earnings (loss) per share |
$ | — | $ | 0.30 | $ | 0.12 | $ | (0.19 | ) | |||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding-basic (2) |
153,052,983 |
153,327,308 |
153,052,983 |
155,725,959 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding-diluted (2) |
153,624,013 |
163,331,348 |
153,661,856 |
155,725,959 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| (1) | Includes stock-based compensation expense of $0.2 million and $8.7 million for the years ended December 31, 2019 and 2020, respectively, and $0.3 million and $61.0 million for the six months ended June 30, 2020 and 2021, respectively. |
| (2) | See Note 13 to our audited financial statements and Note 11 to our unaudited interim financial statements included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted earnings per share and the weighted-average number of shares used in the computation of the per share amounts. |
As of December 31, |
As of June 30, |
|||||||||||
2019 |
2020 |
2021 |
||||||||||
(in thousands) |
||||||||||||
| Balance Sheet Data: |
||||||||||||
| Cash and cash equivalents |
$ | 38,353 | $ | 58,133 | $ | 163,968 | ||||||
| Total assets |
62,598 | 133,855 | 254,254 | |||||||||
| Total liabilities |
23,784 | 36,178 | 50,539 | |||||||||
| Total stockholders’ equity |
38,814 | 97,677 | 203,715 | |||||||||
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(dollars in thousands) |
||||||||||||||||
| Adjusted EBITDA |
$ | 1,728 | $ | 69,094 | $ | 21,947 | $ | 51,141 | ||||||||
| Adjusted EBITDA Margin |
1.6 |
% |
26.3 |
% |
22.8 |
% |
27.2 |
% | ||||||||
| Net cash provided by operating activities |
6,531 | 21,748 | 24,309 | 32,741 | ||||||||||||
| Free cash flow |
1,770 | 19,486 | 23,229 | 31,718 | ||||||||||||
| • | other companies may calculate Adjusted EBITDA and Adjusted EBITDA Margin differently, which reduces their usefulness as a comparative measure; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect other income (loss), net; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect any gain or loss on disposal of assets; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect our tax provision, which reduces cash available to us; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect recurring, non-cash expenses of depreciation and amortization of property and equipment and, although these are non-cash expenses, the assets being depreciated and amortized may have to be replaced in the future; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect the impact of stock-based compensation expense; |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect transaction costs; and |
| • | Adjusted EBITDA and Adjusted EBITDA Margin do not reflect expenses related to non-ordinary course disputes. |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(dollars in thousands) |
||||||||||||||||
| Net income (loss) |
$ | 112 | $ | 49,758 | $ | 18,309 | $ | (29,106 | ) | |||||||
| Add (deduct): |
||||||||||||||||
| Other income (loss), net |
(459 | ) | (136 | ) | (116 | ) | 69 | |||||||||
| Gain/loss on disposal |
120 | 2 | — | — | ||||||||||||
| Provision for income taxes |
— | 8,318 | 2,403 | 13,036 | ||||||||||||
| Depreciation and amortization expense (1) |
517 | 946 | 399 | 656 | ||||||||||||
| Stock-based compensation expense (2) |
179 | 8,713 | 287 | 61,731 | ||||||||||||
| Transaction costs |
— | 296 | — | 339 | ||||||||||||
| Expenses related to non-ordinary course disputes(3) |
1,259 | 1,197 | 665 | 4,416 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | 1,728 | $ | 69,094 | $ | 21,947 | $ | 51,141 | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA Margin |
1.6 |
% |
26.3 |
% |
22.8 |
% |
27.2 |
% | ||||||||
| (1) | Excludes amortization of debt issuance costs included in “Other income (loss), net.” |
| (2) | Includes stock-based compensation expense and payroll taxes related to equity award activity. |
| (3) | Represents legal fees incurred in connection with the litigation claims described in the section titled “Business—Legal Proceedings.” |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(in thousands) |
||||||||||||||||
| Net cash provided by operating activities |
$ | 6,531 | $ | 21,748 | $ | 24,309 | $ | 32,741 | ||||||||
| Less: capital expenditures |
(4,761 | ) | (2,262 | ) | (1,080 | ) | (1,023 | ) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Free cash flow |
$ | 1,770 | $ | 19,486 | $ | 23,229 | $ | 31,718 | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| • | Expanded our community of active customers by 118% from 0.6 million to approximately 1.3 million; |
| • | Increased net revenues from $110.5 million to $263.1 million, representing 138% year-over-year growth; |
| • | Increased gross margin by 50 basis points from 71.8% to 72.3%; |
| • | Improved net operating (loss) income from $(0.3) million to $57.9 million; |
| • | Increased Adjusted EBITDA from $1.7 million to $69.1 million, representing an Adjusted EBITDA margin of 26.3% in 2020; |
| • | Increased cash flow from operations from $6.5 million to $21.7 million; and |
| • | Increased free cash flow from $1.8 million to $19.5 million. |
| • | Expanded our community of active customers by 79.2% from approximately 0.9 million to approximately 1.6 million; |
| • | Increased net revenues from $96.1 million to $188.2 million, representing 95.8% year-over-year growth; |
| • | Increased gross margin by 0.2 percentage points from 72.3% to 72.5%; |
| • | Net operating income (loss) decreased from $20.6 million to $(16.0) million; |
| • | Increased Adjusted EBITDA from $21.9 million to $51.1 million, representing an Adjusted EBITDA margin of 27.2% in 2021; |
| • | Increased cash flow from operations from $24.3 million to $32.7 million; and |
| • | Increased free cash flow from $23.2 million to $31.7 million. |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
| Active customers (in thousands) |
596 | 1,300 | 905 | 1,622 | ||||||||||||
| Average order value |
$ | 95 | $ | 94 | $ | 89 | $ | 101 | ||||||||
| Adjusted EBITDA (in thousands) (1) |
$ | 1,728 | $ | 69,094 | $ | 21,947 | $ | 51,141 | ||||||||
| Adjusted EBITDA Margin (1) |
1.6 | % | 26.3 | % | 22.8 | % | 27.2 | % | ||||||||
| Free cash flow (in thousands) (1) |
$ | 1,770 | $ | 19,486 | $ | 23,229 | $ | 31,718 | ||||||||
| (1) | See the section titled Selected Financial Data—Non-GAAP Financial Measures” for information regarding Adjusted EBITDA, Adjusted EBITDA Margin and free cash flow, including a reconciliation to the most directly comparable financial measure prepared in accordance with U.S. GAAP. |




Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
(in thousands) |
||||||||||||||||
| Statements of Operations Data: |
||||||||||||||||
| Net revenues |
$ | 110,494 | $ | 263,112 | $ | 96,110 | $ | 188,196 | ||||||||
| Cost of goods sold |
31,158 | 72,888 | 26,578 | 51,683 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
79,336 | 190,224 | 69,532 | 136,513 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Selling |
24,840 | 51,896 | 19,644 | 36,337 | ||||||||||||
| Marketing |
33,193 | 38,852 | 16,142 | 26,327 | ||||||||||||
| General and administrative (1) |
21,650 | 41,536 | 13,150 | 89,850 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
79,683 | 132,284 | 48,936 | 152,514 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net (loss) income from operations |
(347 | ) | 57,940 | 20,596 | (16,001 | ) | ||||||||||
| Other income (loss), net |
459 | 136 | 116 | (69 | ) | |||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) before income tax provision |
112 | 58,076 | 20,712 | (16,070 | ) | |||||||||||
| Provision for income taxes |
— | 8,318 | 2,403 | 13,036 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | 112 | $ | 49,758 | $ | 18,309 | $ | (29,106 | ) | |||||||
| |
|
|
|
|
|
|
|
|||||||||
| (1) | Includes stock-based compensation expense of $0.2 million and $8.7 million for the years ended December 31, 2019 and 2020, respectively, and $0.3 million and $61.0 million for the six months ended June 30, 2020 and 2021, respectively. |
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
| Statements of Operations Data, as a percentage of net revenues: |
||||||||||||||||
| Net revenues |
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
| Cost of goods sold |
28.2 | 27.7 | 27.7 | 27.5 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
71.8 | 72.3 | 72.3 | 72.5 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Selling |
22.5 | 19.7 | 20.4 | 19.3 | ||||||||||||
| Marketing |
30.0 | 14.8 | 16.8 | 14.0 | ||||||||||||
| General and administrative |
19.6 | 15.8 | 13.7 | 47.7 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
72.1 | 50.3 | 50.9 | 81.0 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net (loss) income from operations |
(0.3 | ) | 22.0 | 21.4 | (8.5 | ) | ||||||||||
| Other income (loss), net |
0.4 | 0.1 | 0.1 | (0.0 | ) | |||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) before income tax provision |
0.1 | 22.1 | 21.6 | (8.5 | ) | |||||||||||
| Provision for income taxes |
— | 3.2 | 2.5 | 6.9 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
0.1 | % | 18.9 | % | 19.1 | % | (15.5 | )% | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
Years Ended December 31, |
||||||||||||
2019 |
2020 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Net revenues |
$ | 110,494 | $ | 263,112 | 138.1 | % | ||||||
Years Ended December 31, |
||||||||||||
2019 |
2020 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Cost of goods sold |
$ | 31,158 | $ | 72,888 | 133.9 | % | ||||||
| Gross profit |
79,336 | 190,224 | 139.8 | |||||||||
| Gross margin |
71.8 | % | 72.3 | % | 0.5 | % | ||||||
Years Ended December 31, |
||||||||||||
2019 |
2020 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Operating expenses: |
||||||||||||
| Selling |
$ | 24,840 | $ | 51,896 | 108.9 | % | ||||||
| Marketing |
33,193 | 38,852 | 17.0 | |||||||||
| General and administrative |
21,650 | 41,536 | 91.9 | |||||||||
| Total operating expenses |
$ | 79,683 | $ | 132,284 | 66.0 | % | ||||||
Years Ended December 31, |
||||||||||||
2019 |
2020 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Other income, net |
$ | 459 | $ | 136 | (70.4 | )% | ||||||
Years Ended December 31, |
||||||||||||
2019 |
2020 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Provision for income taxes |
— | $ | 8,318 | — | ||||||||
Six Months Ended June 30, |
||||||||||||
2020 |
2021 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Net revenues |
$ | 96,110 | $ | 188,196 | 95.8 | % | ||||||
Six Months Ended June 30, |
||||||||||||
2020 |
2021 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Cost of goods sold |
$ | 26,578 | $ | 51,683 | 94.5 | % | ||||||
| Gross profit |
69,532 | 136,513 | 96.3 | % | ||||||||
| Gross margin |
72.3 | % | 72.5 | % | 0.2 | % | ||||||
Six Months Ended June 30, |
||||||||||||
2020 |
2021 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Selling |
$ | 19,644 | $ | 36,337 | 85.0 | % | ||||||
| Marketing |
16,142 | 26,327 | 63.1 | % | ||||||||
| General and administrative |
13,150 | 89,850 | 583.3 | % | ||||||||
| Total operating expenses |
$ | 48,936 | $ | 152,514 | 211.7 | % | ||||||
Six Months Ended June 30, |
||||||||||||
2020 |
2021 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Other income (loss), net |
$ | 116 | $ | (69 | ) | (159.5 | )% | |||||
Six Months Ended June 30, |
||||||||||||
2020 |
2021 |
% Change |
||||||||||
(in thousands) |
||||||||||||
| Provision for income taxes |
2,403 | $ | 13,036 | 442.5 | % | |||||||
Three Months Ended |
||||||||||||||||||||||||
March 31, 2020 |
June 30, 2020 |
September 30, 2020 |
December 30, 2020 |
March 31, 2021 |
June 30, 2021 |
|||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||
| Net revenues |
$ | 31,967 | $ | 64,143 | $ | 76,809 | $ | 90,193 | $ | 87,079 | $ | 101,117 | ||||||||||||
| Cost of goods sold |
7,655 | 18,923 | 20,176 | 26,134 | 24,719 | 26,964 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Gross profit |
24,312 | 45,220 | 56,633 | 64,059 | 62,360 | 74,153 | ||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||
| Selling |
6,739 | 12,905 | 13,998 | 18,254 | 17,114 | 19,222 | ||||||||||||||||||
| Marketing |
7,337 | 8,805 | 9,655 | 13,055 | 10,840 | 15,488 | ||||||||||||||||||
| General and administrative |
6,200 | 6,950 | 8,407 | 19,979 | 18,346 | 71,504 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total operating expenses |
20,276 | 28,660 | 32,060 | 51,288 | 46,300 | 106,214 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) from operations |
4,036 | 16,560 | 24,573 | 12,771 | 16,060 | (32,061 | ) | |||||||||||||||||
| Other income (loss), net |
98 | 18 | 12 | 8 | (38 | ) | (31 | ) | ||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) before income tax provision |
4,134 | 16,578 | 24,585 | 12,779 | 16,022 | (32,092 | ) | |||||||||||||||||
| Provision for income taxes |
— | 2,403 | 5,262 | 653 | 4,582 | 8,454 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) |
$ | 4,134 | $ | 14,175 | $ | 19,323 | $ | 12,126 | $ | 11,440 | $ | (40,546 | ) | |||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| The following table sets forth our results of operations as a percentage of net revenues for the periods presented: |
| |||||||||||||||||||||||
Three Months Ended |
||||||||||||||||||||||||
March 31, 2020 |
June 30, 2020 |
September 30, 2020 |
December 31, 2020 |
March 31, 2021 |
June 30, 2021 |
|||||||||||||||||||
| Net revenues |
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||
| Cost of goods sold |
23.9 | 29.5 | 26.3 | 29.0 | 28.4 | 26.7 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Gross profit |
76.1 | 70.5 | 73.7 | 71.0 | 71.6 | 73.3 | ||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||
| Selling |
21.1 | 20.1 | 18.2 | 20.2 | 19.7 | 19.0 | ||||||||||||||||||
| Marketing |
23.0 | 13.7 | 12.6 | 14.5 | 12.4 | 15.3 | ||||||||||||||||||
| General and administrative |
19.4 | 10.8 | 10.9 | 22.2 | 21.1 | 70.7 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total operating expenses |
63.4 | 44.7 | 41.7 | 56.9 | 53.2 | 105.0 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net (loss) income from operations |
12.6 | 25.8 | 32.0 | 14.2 | 18.4 | (31.7 | ) | |||||||||||||||||
| Other income (loss), net |
0.3 | 0.0 | 0.0 | 0.0 | 0.0 | (0.0 | ) | |||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) before income tax provision |
12.9 | 25.8 | 32.0 | 14.2 | 18.4 | (31.7 | ) | |||||||||||||||||
| Provision for income taxes |
— | 3.7 | 6.9 | 0.7 | 5.3 | 8.4 | ||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) |
12.9 | % | 22.1 | % | 25.2 | % | 13.4 | % | 13.1 | % | (40.1 | )% | ||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Three Months Ended |
||||||||||||||||||||||||
March 31, 2020 |
June 30, 2020 |
September 30, 2020 |
December 31, 2020 |
March 31, 2021 |
June 30, 2021 |
|||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||
| Net income |
$ | 4,134 | $ | 14,175 | $ | 19,323 | $ | 12,126 | $ | 11,440 | $ | (40,546 | ) | |||||||||||
| Add (deduct): |
||||||||||||||||||||||||
| Other income (loss), net |
(98 | ) | (18 | ) | (12 | ) | (8 | ) | 38 | 31 | ||||||||||||||
| Gain on disposal |
— | — | — | 2 | — | — | ||||||||||||||||||
| Provision for income taxes |
— | 2,403 | 5,262 | 653 | 4,582 | 8,454 | ||||||||||||||||||
| Depreciation and amortization expense (1) |
218 | 181 | 256 | 291 | 313 | 344 | ||||||||||||||||||
| Stock-based compensation expense (2) |
50 | 237 | 693 | 7,733 | 5,015 | 56,716 | ||||||||||||||||||
| Transaction costs |
— | — | — | 296 | 525 | (186 | ) | |||||||||||||||||
| Expenses related to non-ordinary course disputes (3) |
300 | 365 | 206 | 326 | 2,436 | 1,980 | ||||||||||||||||||
| Adjusted EBITDA |
$ | 4,604 | $ | 17,343 | $ | 25,728 | $ | 21,419 | $ | 24,349 | $ | 26,793 | ||||||||||||
| Adjusted EBITDA Margin |
14.4 | % | 27.0 | % | 33.5 | % | 23.7 | % | 28.0 | % | 26.5 | % | ||||||||||||
| (1) | Excludes amortization of debt issuance costs included in “Other income (loss), net.” |
| (2) | Includes stock-based compensation expense and payroll taxes related to equity award activity. |
| (3) | Represents legal fees incurred in connection with the litigation claims described in the section titled “Business—Legal Proceedings.” |
Three Months Ended |
||||||||||||||||||||||||
March 31, 2020 |
June 30, 2020 |
September 30, 2020 |
December 31, 2020 |
March 31, 2021 |
June 30, 2021 |
|||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||
| Net cash (used in) provided by operating activities |
$ | (821 | ) | $ | 25,130 | $ | (1,233 | ) | $ | (1,328 | ) | $ | 16,109 | $ | 16,632 | |||||||||
| Less: capital expenditures |
(972 | ) | (109 | ) | (546 | ) | (635 | ) | (528 | ) | (495 | ) | ||||||||||||
| Free cash flow |
$ | (1,793 | ) | $ | 25,021 | $ | (1,779 | ) | $ | (1,963 | ) | $ | 15,581 | $ | 16,137 | |||||||||
Years Ended December 31, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2020 |
2020 |
2021 |
|||||||||||||
| (in thousands) |
||||||||||||||||
| Cash (used in) provided by operating activities |
$ | 6,531 | $ | 21,748 | $ | 24,309 | $ | 32,741 | ||||||||
| Cash used in investing activities |
(4,761 | ) | (2,262 | ) | (1,080 | ) | (1,023 | ) | ||||||||
| Cash provided by financing activities |
14,000 | 294 | — | 74,117 | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net (decrease) increase in cash and cash equivalents |
$ | 15,770 | $ | 19,780 | $ | 23,229 | $ | 105,835 | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
Payments Due by Period |
||||||||||||||||||||
Total |
Less than 1 Year |
1-3 Years |
3-5 Years |
More than 5 Years |
||||||||||||||||
(in thousands) |
||||||||||||||||||||
| Operating lease commitments |
$19,634 | $ 1,941 | $3,986 | $4,259 | $9,448 | |||||||||||||||
| Inventory purchase obligations |
33,837 | 33,837 | — | — | — | |||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| Total |
$53,471 | $35,778 | $3,986 | $4,259 | $9,448 | |||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| • | identification of the contract, or contracts, with a customer; |
| • | identification of the performance obligations in the contract; |
| • | determination of the transaction price; |
| • | allocation of the transaction price to the performance obligations in the contract; and |
| • | recognition of revenue when, or as, we satisfy a performance obligation. |
| • | Fair Value of Common Stock |
| • | Risk-Free Interest Rate |
| • | Expected Volatility |
| • | Expected Dividend Yield |
| • | Expected Term time-to-vesting |
| • | contemporaneous independent third-party valuations of our common stock; |
| • | the prices at which our common stock was sold in secondary transactions; |
| • | our results of operations, financial position and capital resources; |
| • | industry outlook; |
| • | the lack of marketability of our common stock; |
| • | the fact that the stock option grants involve illiquid securities in a private company; |
| • | the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company, given prevailing market conditions; |
| • | the history and nature of our business, industry trends, and competitive environment; and |
| • | general economic outlook, including economic growth, inflation and unemployment, interest rate environment and global economic trends. |
| • | Working with our community of Ambassadors to provide time, expertise and care to local healthcare institutions, providers and patients through medical giving trips; |
| • | Granting funds through our New Icons initiative to help pay the tuition of selected Awesome Humans who represent the next generation of healthcare; |
| • | Promoting diversity and inclusion in the healthcare profession by donating to, and raising awareness for, organizations with our shared values, such as the National Black Nurses Association and Student National Medical Association; |
| • | Creating a special capsule collection, through which we donated funds to Wild Aid for each product sold within the collection, to help fight poaching and climate change and to protect endangered species; and |
| • | Donating funds and supplies to support rehabilitation efforts following the 2020 wildfires in Australia. |
| • | Expanded our community of active customers by 118% from 0.6 million to approximately 1.3 million; |
| • | Increased net revenues from $110.5 million to $263.1 million, representing 138% year-over-year growth; |
| • | Increased gross margin by 50 basis points from 71.8% to 72.3%; |
| • | Improved net operating (loss) income from $(0.3) million to $57.9 million; |
| • | Increased Adjusted EBITDA from $1.7 million to $69.1 million, representing an Adjusted EBITDA margin of 26.3% in 2020; |
| • | Increased cash flow from operations from $6.5 million to $21.7 million; and |
| • | Increased free cash flow from $1.8 million to $19.5 million. |
| • | Expanded our community of active customers by 79.2% from approximately 0.9 million to approximately 1.6 million; |
| • | Increased net revenues from $96.1 million to $188.2 million, representing 95.8% year-over-year growth; |
| • | Increased gross margin by 0.2 percentage points from 72.3% to 72.5%; |
| • | Net operating income (loss) decreased from $20.6 million to $(16.0) million; |
| • | Increased Adjusted EBITDA from $21.9 million to $51.1 million, representing an Adjusted EBITDA margin of 27.2% in 2021; |
| • | Increased cash flow from operations from $24.3 million to $32.7 million; and |
| • | Increased free cash flow from $23.2 million to $31.7 million. |

| • | Commoditized Products. ill-fitting, uncomfortable, baggy, boxy and lacking in design and functionality, with minimal focus on fabric technology or performance. In addition, any adjacent lifestyle products offered by these manufacturers are extremely limited. |
| • | Brand Obscurity. |
| • | Antiquated Distribution. brick-and-mortar |
| • | Channel Conflict. |
| • | Customer Separation. |
| • | Challenged Margins. |
| • | Resilient Industry with Favorable Long-Term Trends. non-discretionary, replenishment nature of its products and the secular growth of the healthcare sector. |
| • | Increased Demand for Healthcare Professionals. |
| • | Acceleration of eCommerce. |
| • | Attraction to Purpose-Driven Brands. |
| • | Magnified Importance of Technically Advanced Healthcare Apparel. COVID-19 pandemic has magnified the indispensability of healthcare professionals. During a time when the need for high-performance healthcare apparel has never been greater, we quickly rose to the challenge by ramping up production to meet demand and by donating PPE, scrubs, funds and other essential products to frontline workers. Due to the pandemic, more healthcare professionals are choosing to wear medical apparel, and a greater number of hospitals, medical offices and clinics are requiring staff to wear scrubs and other medical apparel. While we demonstrated consistent and significant growth prior to 2020, we believe the pandemic has accelerated awareness of the FIGS brand and a shift in purchasing decisions that will continue to drive future growth. |
| • | Fabric Innovation for Comfort and Performance. four-way stretch to allow for greater mobility, moisture-wicking properties to assist with body temperature regulation and anti-wrinkle for extra convenience. |
| • | Functional Innovation. |
| • | Fit Innovation. (XXS-2XL), six sizes for men (XS-2XL), three lengths for women (petite, regular, tall) and three lengths for men (short, regular, tall). We also offer various maternity offerings. |
| • | Style Innovation. |









| Healthcare Professionals |
Gender |
Age | ||
![]() |
![]() |
![]() | ||
| • | Adam C., M.D.; Emergency Medicine Physician. |
| • | Ana W., R.N.; Emergency Medicine Nurse. |
| • | Lexie R., R.N.; Pediatric Intensive Care Unit Transport Nurse. |
| • | Darien S., M.D., M.B.A.; Emergency Medicine Physician. |
| Name |
Age |
Position(s) | ||||
| Executive Officers: |
||||||
| Heather Hasson |
39 | Co-Founder, Co-Chief Executive Officer and Director | ||||
| Trina Spear |
38 | Co-Founder, Co-Chief Executive Officer and Director | ||||
| Jeffrey D. Lawrence |
48 | Chief Financial Officer | ||||
| Non-Employee Directors: |
||||||
| J. Martin Willhite (1)(3) |
50 | Director | ||||
| Sheila Antrum (1)(2) |
63 | Director | ||||
| Michael Soenen (2)(3) |
51 | Director | ||||
| (1) | Member of the Nominating and Corporate Governance Committee. |
| (2) | Member of the Audit Committee. |
| (3) | Member of the Compensation Committee. |
| • | Class I directors, whose initial term will expire at our first annual meeting of stockholders following the IPO, consist of Trina Spear and Sheila Antrum; |
| • | Class II directors, whose initial term will expire at our second annual meeting of stockholders following the IPO, consist of Heather Hasson and Michael Soenen; and |
| • | Class III directors, whose initial term will expire at our third annual meeting of stockholders following the IPO, consist of J. Martin Willhite. |
| • | appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm; |
| • | discussing with our independent registered public accounting firm their independence from management; |
| • | reviewing with our independent registered public accounting firm the scope and results of their audit; |
| • | approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm; |
| • | overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the interim and annual financial statements that we file with the SEC; |
| • | reviewing and monitoring our accounting principles, accounting policies, financial and accounting controls and compliance with legal and regulatory requirements; and |
| • | establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters. |
| • | reviewing and approving corporate goals and objectives relevant to the compensation of our co-Chief Executive Officers, evaluating our co-Chief Executive Officers’ performance in light of these goals and objectives and setting compensation; |
| • | reviewing and setting or making recommendations to our board of directors regarding the compensation of our other executive officers; and |
| • | reviewing and approving or making recommendations to our board of directors regarding our incentive compensation and equity-based plans and arrangements. |
| • | identifying |
| • | recommending to our board of directors the nominees for election to our board of directors at annual meetings of our stockholders; |
| • | evaluating the overall effectiveness of our board of directors; and |
| • | developing and recommending to our board of directors a set of corporate governance guidelines and principles. |
| Name |
Fees Earned or Paid in Cash |
Option Awards ($) |
Total ($) |
|||||||||
| J. Martin Willhite |
$ | — | $ | — | $ | — | ||||||
| • | Annual Retainer: $50,000 |
| • | Annual Committee Chair Retainer: |
○ |
Audit: $20,000 |
○ |
Compensation: $15,000 |
○ |
Nominating and Governance: $10,000 |
| • | Annual Committee Member (Non-Chair) Retainer: |
○ |
Audit: $10,000 |
○ |
Compensation: $7,500 |
○ |
Nominating and Governance: $5,000 |
| • | Initial Grant |
| • | Annual Grant |
| • | Heather Hasson, Co-Chief Executive Officer; |
| • | Trina Spear, Co-Chief Executive Officer; and |
| • | Jeffrey D. Lawrence, Chief Financial Officer. |
| Name and Principal Position |
Year |
Salary ($) |
Bonus ($) (1) |
Stock Awards ($) (2) |
Option Awards ($) (2) |
All Other Compensation (4) ($) |
Total ($) |
|||||||||||||||||||||
| Heather Hasson |
2020 | 456,154 | 1,000,000 | — | 38,125,365 | 47,329 | 39,628,848 | |||||||||||||||||||||
| Co-Chief Executive Officer |
||||||||||||||||||||||||||||
| Trina Spear |
2020 | 456,154 | 1,000,000 | — | 38,125,365 | 64,212 | 39,645,731 | |||||||||||||||||||||
| Co-Chief Executive Officer |
||||||||||||||||||||||||||||
| Jeffrey D. Lawrence (3) |
2020 | 1,923 | — | — | 5,402,086 | — | 5,404,009 | |||||||||||||||||||||
| Chief Financial Officer |
||||||||||||||||||||||||||||
| (1) | Amounts include discretionary bonuses paid to Mses. Hasson and Spear for their performance in 2020. We provide additional information regarding the annual bonuses in “—Narrative to Summary Compensation Table—2020 Bonuses” below. |
| (2) | Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2020, rather than the amounts paid to or realized by the named individual. In 2020, Mses. Hasson and Spear were granted RSUs that are subject to both service-based and liquidity-based vesting conditions. As required pursuant to SEC disclosure rules, the grant-date fair values of these awards included in the table above were computed based on the probable outcomes of the performance conditions as of the applicable grant date; achievement of the performance conditions for these RSUs was not deemed probable on the grant date and, accordingly, no value is included in the table for these awards. Assuming achievement of the performance conditions, the values of these RSUs to each of Mses. Hasson and Spear, as of the grant date, are $12,206,554. We provide information regarding the assumptions used to calculate the value of all stock awards and option awards made to named executive officers in Note 12 to the financial statements included in this prospectus. |
| (3) | Mr. Lawrence’s employment with us commenced on December 31, 2020; therefore, certain amounts for Mr. Lawrence, such as base salary, reflect a partial year of service. |
| (4) | Amounts include Company reimbursement of legal fees. |
Grant Date |
Option Awards |
Stock Awards |
||||||||||||||||||||||||||||||
| Name |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable |
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
Option Exercise Price ($) |
Option Expiration Date |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
|||||||||||||||||||||||||
| Heather Hasson |
02/22/2018 | (1) |
2,707,497 | 712,503 | — | 0.86 | 02/21/2028 | — | — | |||||||||||||||||||||||
| 06/27/2018 | (2) |
900,000 | — | — | 1.37 | 06/26/2028 | — | — | ||||||||||||||||||||||||
| 06/26/2020 | (3) |
— | — | — | — | — | 2,705,220 | 23,123,619 | ||||||||||||||||||||||||
| 09/16/2020 | (4) |
511,803 | 9,724,257 | — | 5.10 | 09/15/2030 | — | — | ||||||||||||||||||||||||
| Trina Spear |
02/22/2018 | (1) |
6,091,875 | 1,603,125 | — | 0.86 | 02/21/2028 | — | — | |||||||||||||||||||||||
| 06/27/2018 | (2) |
900,000 | — | — | 1.37 | 06/26/2028 | — | — | ||||||||||||||||||||||||
| 06/26/2020 | (3) |
— | — | — | — | — | 2,705,220 | 23,123,619 | ||||||||||||||||||||||||
| 09/16/2020 | (4) |
511,803 | 9,724,257 | — | 5.10 | 09/15/2030 | — | — | ||||||||||||||||||||||||
| Jeffrey D. Lawrence |
12/31/2020 | (5) |
— | 2,047,212 | — | 6.03 | 12/30/2030 | — | — | |||||||||||||||||||||||
| (1) | This option vests and becomes exercisable with respect to 1/48 of the total number of shares underlying the option on each monthly anniversary of the vesting commencement date. In the event of a change in control of our company (as defined in the 2016 Plan), 100% of the shares subject to the option shall vest as of immediately prior to the change in control. |
| (2) | This option vests with respect to 1/48 of the total number of shares underlying the option on each monthly anniversary of the vesting commencement date. In the event of a change in control of our company (as defined in the 2016 Plan), 100% of the shares subject to the option shall vest as of immediately prior to the change in control. This option has an early exercise feature, such that, if early exercised, the unvested shares are subject to a right of repurchase by the Company in connection with a termination of service. |
| (3) | As of December 31, 2020, this RSU award was scheduled to vest upon the satisfaction of both a (i) service-based requirement, which is satisfied in substantially equal quarterly installments over the four-year period following December 31, 2019, and (ii) liquidity event requirement, which was satisfied in connection with the IPO. Please refer to “—2020 RSU Awards” above for additional detail regarding the vesting of this award, including accelerated vesting. |
| (4) | This option vests and becomes exercisable with respect to 1/60 of the total number of shares underlying the option on each monthly anniversary of the grant date. Please refer to “—2020 Stock Option Awards” above for additional detail regarding the vesting of this award, including accelerated vesting. |
| (5) | This option vests and becomes exercisable over a four-year period, with 25% of the total number of shares underlying the option vesting on the first anniversary of Mr. Lawrence’s start date with us, and 1/48 of the total number of shares underlying the option vesting on each monthly anniversary thereafter. If Mr. Lawrence’s employment is terminated by us without “cause” or by him for “good reason” within 12 months following a change in control, then 100% of the then-unvested shares subject to the option will vest in full. |
| • | we have been or are to be a participant; |
| • | the amount involved exceeds or will exceed $120,000; and |
| • | any of our directors, executive officers or holders of more than 5% of our capital stock, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest. |
| • | each of our directors; |
| • | each of our named executive officers; |
| • | all of our directors and executive officers as a group; |
| • | each stockholder known by us to be the beneficial owner of more than 5% of our outstanding shares of Class A common stock or Class B common stock; and |
| • | the selling stockholders. |
| Name of Beneficial Owner |
Shares Beneficially Owned Before this Offering |
% Total Voting Power Before this Offering (1) |
Number of Shares Being Offered |
Shares Beneficially Owned After this Offering |
% Total Voting Power After this Offering (1) |
|||||||||||||||||||||||||||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||||||||||||||||||||||||||||||
Shares |
% |
Shares |
% |
Shares |
% |
Shares |
% |
|||||||||||||||||||||||||||||||||||||
| 5% Stockholders: |
||||||||||||||||||||||||||||||||||||||||||||
| Tulco, LLC (2) |
58,067,602 | 39.3 | 6,300,000 | 47.5 | 44.6 | 5,536,235 | 52,531,367 | 34.8 | 6,300,000 | 51.2 | 45.0 | |||||||||||||||||||||||||||||||||
| Viking Global Opportunities Illiquid Investments Sub-Master LP(3) |
14,742,689 | 10.0 | — | — | 3.6 | — | 14,742,689 | 9.8 | — | — | 3.7 | |||||||||||||||||||||||||||||||||
| Commonwealth of Pennsylvania, Public School Employees’ Retirement System (4) |
9,943,587 | 6.7 | — | — | 2.4 | — | 9,943,587 | 6.6 | — | — | 2.5 | |||||||||||||||||||||||||||||||||
| Named Executive Officers and Directors |
||||||||||||||||||||||||||||||||||||||||||||
| Heather Hasson (5) |
14,807,977 | 9.1 | 1,546,976 | 11.7 | 10.7 | 2,329,316 | 12,478,661 | 7.6 | 1,546,976 | 12.6 | 10.6 | |||||||||||||||||||||||||||||||||
| Catherine Spear (6) |
10,933,477 | 6.9 | 5,417,083 | 40.8 | 28.1 | 961,152 | 10,933,477 | 6.8 | 4,455,931 | 36.2 | 24.5 | |||||||||||||||||||||||||||||||||
| Jeffrey D. Lawrence |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| J. Martin Willhite (2) |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Sheila Antrum |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Michael Soenen |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| All executive officers and directors as a group (six persons) (7) |
25,741,455 | 14.8 | 6,964,059 | 52.5 | 37.6 | 3,290,468 | 23,412,139 | 13.4 | 6,002,907 | 48.8 | 34.1 | |||||||||||||||||||||||||||||||||
| * | Represents beneficial ownership of less than 1% of our outstanding shares of common stock. |
| (1) | Percentage of total voting power represents voting power with respect to all shares of our Class A common stock and Class B common stock, as a single class. The holders of our Class B common stock are entitled to 20 votes per share and holders of our Class A common stock are entitled to one vote per share. See the section titled “Description of Capital Stock—Common Stock” for more information about the voting rights of our Class A common stock and Class B common stock. |
| (2) | Thomas J. Tull, founder, Chairman and Chief Executive Officer of Tulco, LLC and a member of its board of directors, may control Tulco, LLC. Mr. Tull may be deemed to have or share beneficial ownership of the Class A and Class B common stock held directly by Tulco, LLC. J. Martin Willhite, a member of our board of directors, is Vice Chairman of Tulco, LLC and a member of its board of directors. The mailing address of Tulco, LLC and Messrs. Tull and Willhite is 61 E. Colorado Blvd., Unit 200, Pasadena, CA 91105. |
| (3) | Viking Global Opportunities Illiquid Investments Sub-Master LP (the “Opportunities Fund”) has the authority to dispose of and vote the Class A common stock directly owned by it, which power may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (“Opportunities GP”), and by Viking Global Investors LP (“VGI”), which provides managerial services to Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities GP LLC, the sole member of Opportunities GP, have shared authority to direct the voting and disposition of investments beneficially owned by VGI, Opportunities GP and the Opportunities Fund. The address of each of the entities is c/o Viking Global Investors LP, 55 Railroad Avenue, Greenwich, Connecticut 06830. |
| (4) | James H. Grossman, Jr., the Authorized Person for the Commonwealth of Pennsylvania, Public School Employees’ Retirement System, holds voting and investment power over the shares of Class A common stock held by the Commonwealth of Pennsylvania, Public School Employees’ Retirement System. The address of Commonwealth of Pennsylvania, Public School Employees’ Retirement System is 5 North Fifth Street, Harrisburg, Pennsylvania 17101. |
| (5) | Consists of (a) 942,453 shares of Class B common stock held by the Maple Tree Irrevocable Trust, (b) 14,631,799 shares of Class A common stock issuable upon the exercise of stock options exercisable within 60 days of August 31, 2021 and (c) 176,178 shares of Class A common stock issuable upon the settlement of RSUs vesting within 60 days of August 31, 2021. Assuming the exchange of all of the shares of Class A common stock underlying Ms. Hasson’s eligible options and RSUs vesting within 60 days of August 31, 2021 for shares of Class B common stock pursuant to the Equity Award Exchange Agreement, Ms. Hasson would have total voting power after this offering of 43.4%. |
| (6) | Consists of (a) 2,939,544 shares of Class B common stock held by the Catherine Spear Revocable Trust, (b) 983,016 shares of Class B common stock held by the Wingaersheek Irrevocable Trust I, (c) 983,016 shares of Class B common stock held by the Wingaersheek Irrevocable Trust II, (d) 10,757,299 shares of Class A common stock issuable upon the exercise of stock options exercisable within 60 days of August 31, 2021 and (e) 176,178 shares of Class A common stock issuable upon the settlement of RSUs vesting within 60 days of August 31, 2021. Assuming the exchange of all of the shares of Class A common stock underlying Ms. Spear’s eligible options and RSUs vesting within 60 days of August 31, 2021 for shares of Class B common stock pursuant to the Equity Award Exchange Agreement, Ms. Spear would have total voting power after this offering of 50.0%. |
| (7) | Consists of (a) 6,964,059 shares of Class B common stock, (b) 25,389,098 shares of Class A common stock issuable upon the exercise of stock options exercisable within 60 days of August 31, 2021 and (c) 352,357 shares of Class A common stock issuable upon the settlement of RSUs vesting within 60 days of August 31, 2021. Assuming the exchange of the shares of Class A common stock underlying all of Mses. Hasson’s and Spear’s eligible options and RSUs vesting within 60 days of August 31, 2021 for shares of Class B common stock pursuant to the Equity Award Exchange Agreement, Mses. Hasson and Spear would have total voting power after this offering of 68.0%. |
| • | 147,730,670 shares of our Class A common stock, held by approximately 41 stockholders of record; and |
| • | 13,264,059 shares of our Class B common stock, held by seven stockholders of record. |
| • | if we were to seek to amend our amended and restated certificate of incorporation to increase or decrease the par value of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; and |
| • | if we were to seek to amend our amended and restated certificate of incorporation in a manner that alters or changes the powers, preferences or special rights of a class of our capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. |
| • | prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
| • | the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
| • | at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. |
| • | Dual-Class Common Stock |
| • | Board of Directors Vacancies |
| • | Classified Board |
| • | Directors Removed Only for Cause |
| • | Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws two-thirds of the voting power of all of the then |
| outstanding shares of voting stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board, removal of directors, special meetings, actions by written consent, and designation of our preferred stock. In addition, the affirmative vote of holders of 66 2/3% of the voting power of each of our Class A common stock and Class B common stock, voting separately by class, is required to amend the provisions of our amended and restated certificate of incorporation relating to the terms of our Class B common stock. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then outstanding shares of voting stock is required to amend or repeal our amended and restated bylaws, although our amended and restated bylaws may be amended by a simple majority vote of our board of directors. |
| • | Stockholder Action; Special Meeting of Stockholders |
| • | Advance Notice Requirements for Stockholder Proposals and Director Nominations |
| • | No Cumulative Voting |
| • | Issuance of Undesignated Preferred Stock |
| • | Choice of Forum |
| amended or restated) or as to which the DGCL confers exclusive jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware, and (B) the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision shall not apply to claims seeking to enforce any liability or duty created by the Exchange Act. Our amended and restated certificate of incorporation also provides that, to the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to have notice of and consented to the foregoing. By agreeing to this provision, however, stockholders have not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. |
| • | beginning on the date of this prospectus, all of the shares of Class A common stock sold in this offering, will be immediately available for sale in the public market; and |
| • | the remainder of the shares of our common stock will be eligible for sale in the public market beginning on the earlier of 180 days after the date of the IPO Prospectus and the second full trading day following our second public release of quarterly or annual financial results following the date of the IPO Prospectus. |
| • | 1% of the number of shares of our Class A common stock then outstanding, which will equal approximately 1,510,211 shares immediately after this offering; or |
| • | the average weekly trading volume of our Class A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale. |
| • | U.S. expatriates and former citizens or long-term residents of the United States; |
| • | persons holding our Class A common stock as part of a hedge, straddle, synthetic security or other risk reduction strategy or as part of a conversion transaction or other integrated investment; |
| • | banks, insurance companies, and other financial institutions; |
| • | brokers, dealers or traders in securities; |
| • | “controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax; |
| • | partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); |
| • | tax-exempt organizations or governmental organizations; |
| • | persons deemed to sell our Class A common stock under the constructive sale provisions of the Code; |
| • | persons who hold or receive our Class A common stock pursuant to the exercise of any employee stock option or otherwise as compensation; |
| • | persons that own, or are deemed to own, during the applicable testing period, more than 5% of our outstanding capital stock (except to the extent specifically set forth below); |
| • | tax-qualified retirement plans; and |
| • | “qualified foreign pension funds” as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. |
| • | an individual who is a citizen or resident of the United States; |
| • | a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; |
| • | an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
| • | a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. |
| • | the gain is effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); |
| • | the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or |
| • | our Class A common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC at any time during the five-year period preceding such disposition (or the Non-U.S. Holders’ holding period, if shorter), for U.S. federal income tax purposes. |
| Underwriters |
Number of Shares |
|||
| Goldman Sachs & Co. LLC |
||||
| Morgan Stanley & Co. LLC |
||||
| Barclays Capital Inc. |
||||
| Credit Suisse Securities (USA) LLC |
||||
| BofA Securities, Inc. |
||||
| Cowen and Company, LLC |
||||
| Guggenheim Securities, LLC |
||||
| KeyBanc Capital Markets Inc. |
||||
| Oppenheimer & Co. Inc. |
||||
| Piper Sandler & Co. |
||||
| Telsey Advisory Group LLC |
||||
| Academy Securities, Inc. |
||||
| R. Seelaus & Co., LLC |
||||
| Samuel A. Ramirez & Company, Inc. |
||||
| Siebert Williams Shank & Co., LLC |
||||
| |
|
|||
| Total |
8,826,703 | |||
| |
|
|||
No Exercise |
Full Exercise |
|||||||
| Per Share |
$ | $ | ||||||
| Total |
$ | $ | ||||||
| (a) | to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation; |
| (b) | to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or |
| (c) | in any other circumstances falling within Article 1(4) of the Prospectus Regulation, |
| (d) | to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; |
| (e) | to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or |
| (f) | in any other circumstances falling within Section 86 of the FSMA. |
Page |
||||
| F-2 | ||||
| F-3 | ||||
| F-4 | ||||
| F-5 | ||||
| F-6 | ||||
| F-7 | ||||
| F-24 | ||||
| F-26 | ||||
| F-27 | ||||
| F-28 | ||||
| F-29 | ||||
As of December 31, |
||||||||
Assets |
2019 |
2020 |
||||||
| Current assets |
||||||||
| Cash and cash equivalents |
$ | $ | ||||||
| Accounts receivable |
||||||||
| Inventory, net |
||||||||
| Prepaid expenses and other current assets |
||||||||
| |
|
|
|
|||||
| Total current assets |
||||||||
| Non-current assets |
||||||||
| Property and equipment, net |
||||||||
| Deferred tax assets |
||||||||
| Other assets |
||||||||
| |
|
|
|
|||||
| Total non-current assets |
||||||||
| |
|
|
|
|||||
| Total assets |
$ | $ | ||||||
| |
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Current liabilities |
||||||||
| Accounts payable |
$ | $ | ||||||
| Accrued expenses |
||||||||
| Accrued compensation and benefits |
||||||||
| Sales tax payable |
||||||||
| Gift card liability |
||||||||
| Deferred revenue |
||||||||
| Returns reserve |
||||||||
| Income tax payable |
||||||||
| |
|
|
|
|||||
| Total current liabilities |
||||||||
| Non-current liabilities |
||||||||
| Deferred rent and lease incentive |
||||||||
| |
|
|
|
|||||
| Total liabilities |
||||||||
| |
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Stockholders’ equity |
||||||||
| Common stock—par value $ |
||||||||
| Additional paid-in capital |
||||||||
| (Accumulated deficit) retained earnings |
( |
) | ||||||
| |
|
|
|
|||||
| Total stockholders’ equity |
||||||||
| |
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | $ | ||||||
| |
|
|
|
|||||
Years ended December 31, |
||||||||
2019 |
2020 |
|||||||
| Net revenues |
$ | $ | ||||||
| Cost of goods sold |
||||||||
| |
|
|
|
|||||
| Gross profit |
||||||||
| Operating expenses |
||||||||
| Selling |
||||||||
| Marketing |
||||||||
| General and administrative |
||||||||
| |
|
|
|
|||||
| Total operating expenses |
||||||||
| |
|
|
|
|||||
| Net (loss) income from operations |
( |
) | ||||||
| Other income, net |
||||||||
| Interest income |
||||||||
| Other expense |
( |
) | ||||||
| |
|
|
|
|||||
| Total other income, net |
||||||||
| |
|
|
|
|||||
| Net income before provision for income taxes |
||||||||
| Provision for income taxes |
||||||||
| Net income and comprehensive income |
$ |
$ |
||||||
| |
|
|
|
|||||
| Basic earnings per share |
$ |
$ |
||||||
| |
|
|
|
|||||
| Diluted earnings per share |
$ |
$ |
||||||
| |
|
|
|
|||||
| Weighted-average shares outstanding—basic |
||||||||
| |
|
|
|
|||||
| Weighted-average shares outstanding—diluted |
||||||||
| |
|
|
|
|||||
Common Stock |
||||||||||||||||||||||||
Shares |
Amount |
Contribution Receivable |
Additional Paid-in Capital |
(Accumulated Deficit) Retained Earnings |
Total Stockholders’ Equity |
|||||||||||||||||||
| December 31, 2018 |
$ | $ | ( |
) | $ | $ | ( |
) | $ | |||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Stock-based compensation |
— | — | — | — | ||||||||||||||||||||
| Contributed capital |
— | — | — | — | ||||||||||||||||||||
| Net income |
— | — | — | — | ||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| December 31, 2019 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Stock-based compensation |
— | — | — | — | ||||||||||||||||||||
| Stock option exercises |
— | — | — | |||||||||||||||||||||
| Net income |
— | — | — | — | ||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| December 31, 2020 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Years Ended December 31, |
||||||||
Cash flows from operating activities: |
2019 |
2020 |
||||||
| Net income |
$ | $ | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
| Depreciation and amortization expense |
||||||||
| Benefit for deferred income taxes |
( |
) | ||||||
| Loss on disposal of property and equipment |
||||||||
| Stock-based compensation |
||||||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
( |
) | ( |
) | ||||
| Inventory |
( |
) | ( |
) | ||||
| Prepaid expenses and other current assets |
( |
) | ||||||
| Other assets |
( |
) | ||||||
| Accounts payable |
||||||||
| Accrued expenses |
||||||||
| Deferred revenue |
( |
) | ||||||
| Accrued compensation and benefits |
||||||||
| Returns reserve |
||||||||
| Sales tax payable |
||||||||
| Income tax payable |
||||||||
| Gift card liability |
||||||||
| Deferred rent and lease incentive |
||||||||
| |
|
|
|
|||||
| Net cash provided by operating activities |
||||||||
| Cash flows from investing activities: |
||||||||
| Purchases of property and equipment |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Net cash used in investing activities |
( |
) | ( |
) | ||||
| Cash flows from financing activities: |
||||||||
| Payment of financing costs |
( |
) | ||||||
| Proceeds from contributed capital |
||||||||
| Proceeds from stock option exercises |
||||||||
| |
|
|
|
|||||
| Net cash provided by financing activities |
||||||||
| |
|
|
|
|||||
| Net increase in cash and cash equivalents |
||||||||
| Cash and cash equivalents, beginning of year |
||||||||
| |
|
|
|
|||||
| Cash and cash equivalents, end of year |
$ | $ | ||||||
| |
|
|
|
|||||
| Supplemental disclosures: |
||||||||
| Income taxes paid |
$ | $ | ||||||
| Property and equipment in accounts payable and accrued expenses |
$ | $ | ||||||
Estimated useful life (years) | ||
| Furniture and fixtures |
||
| Office equipment |
||
| Machinery and equipment |
||
| Computer equipment |
||
| Software and website development |
||
| Leasehold improvements |
the estimated life of the asset |
Years ended December 31, |
||||||||
2019 |
2020 |
|||||||
| By geography: |
||||||||
| United States |
$ | $ | ||||||
| Rest of the world |
||||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
| By product: |
||||||||
| Scrubs |
$ | $ | ||||||
| Non-scrubs |
||||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
| • | Risk-free interest rate—determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. |
| • | Expected volatility—as there is no public market for its common stock, the Company determines the volatility for awards granted based on an analysis of reported data for a group of peer companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. |
| • | Expected dividend yield—the Company has not paid, and does not currently anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. |
| • | Expected term—the expected term of the Company’s stock options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options, which calculates the expected term as the average of the time-to-vesting |
| • | Fair value of common stock—the fair value of the Company’s common stock has been determined on input from management and approved by the Board, utilizing the valuation of the Company’s enterprise value determined utilizing various methods, including the guideline public company method or a weighting of the guideline public company method and discounted cash flow method. The total enterprise value is then allocated to the various outstanding equity instruments, including the underlying common stock, utilizing the option-pricing model or private secondary transactions or a weighting of them. |
Fair Value Measurement as of December 31, 2019 |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets |
||||||||||||||||
Money market funds |
$ | $ | $ | $ | ||||||||||||
| $ | $ | $ | $ | |||||||||||||
Fair Value Measurement as of December 31, 2020 |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Assets |
||||||||||||||||
Money market funds |
$ | $ | $ | $ | ||||||||||||
| $ | $ | $ | $ | |||||||||||||
December 31, |
||||||||
2019 |
2020 |
|||||||
Trade |
$ | $ | ||||||
Other |
||||||||
| $ | $ | |||||||
December 31, |
||||||||
2019 |
2020 |
|||||||
Inventory deposits |
$ | $ | ||||||
Prepaid expenses |
||||||||
Prepaid taxes |
||||||||
Sample kits |
||||||||
Other prepaid expenses and current assets |
||||||||
| $ | $ | |||||||
December 31, |
||||||||
2019 |
2020 |
|||||||
Furniture and fixtures |
$ | $ | ||||||
Office equipment |
||||||||
Machinery and equipment |
||||||||
Computer equipment |
||||||||
Software and website design |
||||||||
Vehicles |
||||||||
Leasehold improvements |
||||||||
Capital projects in progress |
||||||||
Total property and equipment |
||||||||
Less: accumulated depreciation and amortization |
( |
) | ( |
) | ||||
Property and equipment, net |
$ | $ | ||||||
December 31, |
||||||||
2019 |
2020 |
|||||||
Accrued inventory |
$ | $ | ||||||
Accrued shipping |
||||||||
Other accrued expenses |
||||||||
| $ | $ | |||||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
| $ |
Year Ended December 31, |
||||
2020 |
||||
Current income tax provision |
||||
Federal |
$ | |||
State |
||||
Total current provision |
||||
Deferred income tax benefit |
||||
Federal |
( |
) | ||
State |
( |
) | ||
Total deferred benefit |
( |
) | ||
Provision for income taxes |
$ | |||
December 31, |
||||||||
2019 |
2020 |
|||||||
| Tax at U.S. statutory rate |
$ | $ | ||||||
| State taxes, net of federal benefit |
||||||||
| Non-deductible expenses |
( |
) | ||||||
| Change in valuation allowance |
( |
) | ( |
) | ||||
| Other |
||||||||
| |
|
|
|
|||||
| Provision for income taxes |
$ | $ | ||||||
| |
|
|
|
|||||
December 31, |
||||||||
2019 |
2020 |
|||||||
| Deferred tax assets |
||||||||
| Net operating losses |
$ | $ | ||||||
| Uniform capitalization adjustment to inventory |
||||||||
| Stock-based compensation |
||||||||
| Accrued compensation and benefits |
||||||||
| Tenant improvement allowance |
||||||||
| Inventory reserve |
||||||||
| Deferred rent |
||||||||
| Returns reserve |
||||||||
| Sales tax accrual |
||||||||
| Other |
||||||||
| |
|
|
|
|||||
| Total deferred tax assets |
||||||||
| Less: valuation allowance |
( |
) | ||||||
| |
|
|
|
|||||
| Total net deferred tax assets |
||||||||
| Deferred Tax Liabilities |
||||||||
| Property and equipment |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total deferred tax liabilities |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Net deferred tax assets |
$ | $ | ||||||
| |
|
|
|
|||||
December 31, | ||||
2019 |
2020 | |||
| Risk free interest rate |
||||
| Expected volatility |
||||
| Expected dividend yield |
||||
| Expected term (in years) |
||||
Stock Options Outstanding |
||||||||||||
Number of Shares |
Weighted- Average Exercise Price (per share) |
Weighted- Average Remaining Contractual Term (in years) |
||||||||||
| Outstanding at December 31, 2018 |
$ | |||||||||||
| Granted |
||||||||||||
| Exercised |
||||||||||||
| Forfeited |
( |
) | ||||||||||
| |
|
|
|
|||||||||
| Outstanding at December 31, 2019 |
$ | |||||||||||
| |
|
|
|
|||||||||
| Granted |
||||||||||||
| Exercised |
( |
) | ||||||||||
| Forfeited |
( |
) | ||||||||||
| |
|
|
|
|||||||||
| Outstanding at December 31, 2020 |
$ | |||||||||||
| |
|
|
|
|||||||||
| Exercisable at December 31, 2019 |
$ | |||||||||||
| |
|
|
|
|||||||||
| Exercisable at December 31, 2020 |
$ | |||||||||||
| |
|
|
|
|||||||||
Years Ended December 31, |
||||||||
2019 |
2020 |
|||||||
| Numerator: |
||||||||
| Net income basic and diluted |
$ | $ | ||||||
| Denominator: |
||||||||
| Weighted-average shares—basic |
||||||||
| Effect of dilutive stock options |
||||||||
| |
|
|
|
|||||
| Weighted-average shares—diluted |
||||||||
| |
|
|
|
|||||
| Earnings per share: |
||||||||
| Basic earnings per share |
$ | $ | ||||||
| Effect of dilutive stock options |
( |
) | ||||||
| Diluted earnings per share |
$ | $ | ||||||
Years Ended December 31, |
||||||||
2019 |
2020 |
|||||||
| Stock options to purchase common stock |
||||||||
| |
|
|
|
|||||
As of |
||||||||
December 31, |
June 30, |
|||||||
2020 |
2021 |
|||||||
(Unaudited) |
||||||||
Assets |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable |
||||||||
Due from related party |
||||||||
Inventory, net |
||||||||
Prepaid expenses and other current assets |
||||||||
Total current assets |
||||||||
Non-current assets |
||||||||
Property and equipment, net |
||||||||
Deferred tax assets |
||||||||
Other assets |
||||||||
Total non-current assets |
||||||||
Total assets |
$ |
$ |
||||||
Liabilities and stockholders’ equity |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Accrued compensation and benefits |
||||||||
Sales tax payable |
||||||||
Gift card liability |
||||||||
Deferred revenue |
||||||||
Returns reserve |
||||||||
Income tax payable |
||||||||
Total current liabilities |
||||||||
Non-current liabilities |
||||||||
Deferred rent and lease incentive |
||||||||
Total liabilities |
||||||||
As of |
||||||||
December 31, |
June 30, |
|||||||
2020 |
2021 |
|||||||
(Unaudited) |
||||||||
| Commitments and contingencies |
||||||||
| Stockholders’ equity |
||||||||
| Common stock—par value $ |
||||||||
| Class A Common stock—par value $ authorized as of December 31, 2020 and June 30, 2021, respectively; |
||||||||
| Class B Common stock—par value $ authorized as of December 31, 2020 and June 30, 2021, respectively; |
||||||||
| Preferred stock—par value $ authorized as of December 31, 2020 and June 30, 2021, respectively; |
||||||||
| Additional paid-in capital |
||||||||
| Retained earnings (accumulated deficit) |
( |
) | ||||||
| |
|
|
|
|||||
| Total stockholders’ equity |
||||||||
| |
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ |
$ |
||||||
| |
|
|
|
|||||
Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
2020 |
2021 |
2020 |
2021 |
|||||||||||||
| Net revenues |
$ | $ | $ | $ | ||||||||||||
| Cost of goods sold |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
||||||||||||||||
| Operating expenses |
||||||||||||||||
| Selling |
||||||||||||||||
| Marketing |
||||||||||||||||
| General and administrative |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) from operations |
( |
) | ( |
) | ||||||||||||
| Other income (loss), net |
||||||||||||||||
| Interest income (expense) |
( |
) | ( |
) | ||||||||||||
| Other expense |
( |
) | ( |
) | ( |
) | ||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total other income (loss), net |
( |
) |
( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) before provision for income taxes |
( |
) | ( |
) | ||||||||||||
| Provision for income taxes |
||||||||||||||||
| Net income (loss) and comprehensive income (loss) |
$ |
$ |
( |
) |
$ |
$ |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Earnings (loss) attributable to Class A and Class B common stockholders |
||||||||||||||||
| Basic earnings (loss) per share |
$ |
$ |
( |
) |
$ |
$ |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Diluted earnings (loss) per share |
$ |
$ |
( |
) |
$ |
$ |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding—basic |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding—diluted |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Common Stock |
Class A Common Stock |
Class B Common Stock |
Additional Paid-in Capital |
(Accumulated Deficit) Retained Earnings |
Total Stockholders’ Equity |
|||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||||
December 31, 2019 |
$ |
$ |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net income |
— | — | — | |||||||||||||||||||||||||||||||||
March 31, 2020 |
$ |
— |
$ |
— |
— |
$ |
— |
$ |
$ |
( |
) |
$ |
||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Net income |
— | — | — | |||||||||||||||||||||||||||||||||
June 30, 2020 |
$ |
$ |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||||||||||||||||
Common Stock |
Class A Common Stock |
Class B Common Stock |
Additional Paid-in Capital |
(Accumulated Deficit) Retained Earnings |
Total Stockholders’ Equity |
|||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||||
December 31, 2020 |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Stock option exercises |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Net income |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
March 31, 2021 |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||||||||||
Issuance of Class A Common Stock upon exchange of Common Stock |
( |
) | ( |
) | — | — | — | — | — | |||||||||||||||||||||||||||
Issuance of Class B Common Stock upon exchange of Common Stock |
( |
) | ( |
) | — | — | — | — | ||||||||||||||||||||||||||||
Issuance of Class A Common Stock upon initial public offering, net of offering costs |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Issuance of Class A Common Stock upon vesting of Restricted Stock, net of tax withholdings |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Issuance of Class B Common Stock upon exchange of Class A Restricted Stock |
— | — | ( |
) | — | — | — | — | — | |||||||||||||||||||||||||||
Restricted Stock surrendered for employees’ tax liability |
— | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Stock option exercises |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||
June 30, 2021 |
$ |
$ |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||||||||||||||||
Six months ended June 30, |
||||||||
2020 |
2021 |
|||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||||||
Depreciation and amortization expense |
||||||||
Provision (benefit) for deferred income taxes |
( |
) | ||||||
Stock-based compensation |
||||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
( |
) | ||||||
Due from related party |
( |
) | ||||||
Inventory |
( |
) | ( |
) | ||||
Prepaid expenses and other current assets |
( |
) | ( |
) | ||||
Other assets |
( |
) | ||||||
Accounts payable |
( |
) | ||||||
Accrued expenses |
||||||||
Deferred revenue |
( |
) | ||||||
Accrued compensation and benefits |
( |
) | ( |
) | ||||
Returns reserve |
||||||||
Sales tax payable |
||||||||
Income tax payable |
||||||||
Gift card liability |
||||||||
Deferred rent and lease incentive |
( |
) | ||||||
Net cash provided by operating activities |
||||||||
Cash flows from investing activities: |
||||||||
Purchases of property and equipment |
( |
) | ( |
) | ||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Cash flows from financing activities: |
||||||||
Proceeds from issuance of Class A Common Stock in initial public offering, net of underwriting discounts |
||||||||
Payments of initial public offering issuance costs, net of reimbursements |
( |
) | ||||||
Proceeds from stock option exercises |
||||||||
Tax payments related to net share settlements on restricted stock units |
( |
) | ||||||
Net cash provided by financing activities |
||||||||
Net increase in cash and cash equivalents |
||||||||
Cash and cash equivalents, beginning of period |
||||||||
Cash and cash equivalents, end of period |
$ | $ | ||||||
Supplemental disclosures: |
||||||||
Property and equipment included in accounts payable and accrued expenses |
$ | $ | ||||||
Deferred offering costs recorded in stockholders’ equity upon initial public offering |
$ | $ | ||||||
1. |
DESCRIPTION OF BUSINESS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
2020 |
2021 |
2020 |
2021 |
|||||||||||||
| By geography: |
||||||||||||||||
| United States |
$ | $ | $ | $ | ||||||||||||
| Rest of the world |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| $ | $ | $ | $ | |||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| By product: |
||||||||||||||||
| Scrubs |
$ | $ | $ | $ | ||||||||||||
| Non-scrubs |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| $ | $ | $ | $ | |||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
3. |
FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES |
Fair Value Measurement as of December 31, 2020 |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
| Assets |
||||||||||||||||
| Money market funds |
$ | $ | $ | $ | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| $ | $ | $ | $ | |||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Fair Value Measurement as of June 30, 2021 |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
| Assets |
||||||||||||||||
| Money market funds |
$ | $ | $ | $ | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| $ | $ | $ | $ | |||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
4. |
PREPAID EXPENSES AND OTHER CURRENT ASSETS |
December 31, 2020 |
June 30, 2021 |
|||||||
| Inventory deposits |
$ | $ | ||||||
| Prepaid expenses |
||||||||
| Prepaid taxes |
||||||||
| Sample kits |
||||||||
| Other prepaid expenses and current assets |
||||||||
| |
|
|
|
|||||
| $ | $ | |||||||
| |
|
|
|
|||||
5. |
PROPERTY AND EQUIPMENT, NET |
December 31, 2020 |
June 30, 2021 |
|||||||
| Furniture and fixtures |
$ | $ | ||||||
| Office equipment |
||||||||
| Machinery and equipment |
||||||||
| Computer equipment |
||||||||
| Software and website design |
||||||||
| Leasehold improvements |
||||||||
| Capital projects in progress |
||||||||
| |
|
|
|
|||||
| Total property and equipment |
||||||||
| Less: accumulated depreciation and amortization |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Property and equipment, net |
$ | $ | ||||||
| |
|
|
|
|||||
6. |
ACCRUED EXPENSES |
December 31, 2020 |
June 30, 2021 |
|||||||
| Accrued inventory |
$ | $ | ||||||
| Accrued shipping |
||||||||
| Accrued selling expenses |
||||||||
| Accrued legal expenses |
||||||||
| Accrued marketing expenses |
||||||||
| Credit card liabilities |
||||||||
| Other accrued expenses |
||||||||
| |
|
|
|
|||||
| $ | $ | |||||||
| |
|
|
|
|||||
7. |
FINANCING ARRANGEMENTS |
8. |
COMMITMENTS AND CONTINGENCIES |
| 2021 |
$ | |||
| 2022 |
||||
| 2023 |
||||
| 2024 |
||||
| 2025 |
||||
| Thereafter |
||||
| |
|
|||
| $ |
9. |
INCOME TAXES |
10. |
STOCK-BASED COMPENSATION |
Stock Options Outstanding |
||||||||||||||||
Number of Shares |
Weighted Average Exercise Price (per share) |
Weighted Average Remaining Contractual Term (in years) |
Aggregate Intrinsic Value (in millions) |
|||||||||||||
Outstanding at December 31, 2020 |
$ | $ | ||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited |
( |
) | ||||||||||||||
Outstanding at June 30, 2021 |
$ | $ | ||||||||||||||
Number of Shares |
Weighted average grant date fair value per share |
|||||||
Unvested restricted stock at December 31, 2020 |
$ | |||||||
Granted |
||||||||
Vested |
( |
) | ||||||
Forfeited |
( |
) | ||||||
Unvested restricted stock at June 30, 2021 |
$ | |||||||
11. |
EARNINGS (LOSS) PER SHARE |
Three months ended June 30, |
For the six months ended June 30, |
|||||||||||||||
2020 |
2021 |
2020 |
2021 |
|||||||||||||
Numerator: |
||||||||||||||||
Net income (loss) |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
Denominator: |
||||||||||||||||
Weighted-average shares—basic |
||||||||||||||||
Effect of dilutive stock options |
||||||||||||||||
Weighted-average shares—diluted |
||||||||||||||||
Earnings per share: |
||||||||||||||||
Basic earnings (loss) per share |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
Effect of dilutive stock options |
||||||||||||||||
Diluted earnings (loss) per share |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
2020 |
2021 |
2020 |
2021 |
|||||||||||||
Stock options to purchase common stock |
||||||||||||||||
Restricted stock units |
||||||||||||||||
12. |
EMPLOYEE BENEFIT PLAN |
13. |
RELATED PARTY TRANSACTIONS |
14. |
SUBSEQUENT EVENTS |

Item 13. |
Other Expenses of Issuance and Distribution. |
Amount |
||||
| Securities and Exchange Commission registration fee |
$ | 46,812 | ||
| FINRA filing fee |
65,511 | |||
| Accountants’ fees and expenses |
650,000 | |||
| Legal fees and expenses |
500,000 | |||
| Transfer Agent’s fees and expenses |
5,000 | |||
| Printing and engraving expenses |
150,000 | |||
| Miscellaneous |
82,677 | |||
| |
|
|||
| Total expenses |
$ | 1,500,000 | ||
| |
|
|||
Item 14. |
Indemnification of Directors and Officers. |
Item 15. |
Recent Sales of Unregistered Securities. |
| 1. | Since January 1, 2018, we have granted stock options to employees and consultants, covering an aggregate of 44,674,200 shares of our common stock under our 2016 Equity Incentive Plan, at exercise prices ranging from $0.07 to $11.17 per share, and have issued 2,217,561 shares of common stock upon exercise of stock options under our 2016 Equity Incentive Plan with an aggregate exercise price of approximately $1.0 million. |
| 2. | Since January 1, 2018, we have granted restricted stock units to employees representing an aggregate of 5,410,440 shares of common stock under our 2016 Equity Incentive Plan. |
Item 16. |
Exhibits and Financial Statement Schedules. |
| (a) | Exhibits. |
Incorporated by Reference |
Filed Herewith | |||||||||||
| Exhibit Number |
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date |
|||||||
| 10.11 | Form of Exchange Agreement by and among FIGS, Inc., Heather Hasson, Catherine Spear, Tulco, LLC and certain related entities. | S-1/A |
333-255797 |
10.18 | 5/20/2021 | |||||||
| 10.12 | Form of Equity Award Exchange Right Agreement between FIGS, Inc. and each of Heather Hasson and Catherine Spear. | S-1/A |
333-255797 |
10.19 | 5/20/2021 | |||||||
| 10.13 | Credit Agreement by and between FIGS, Inc. and Bank of America, N.A., dated as of September 7, 2021. | 8-K | 001-40448 | 10.1 | 9/10/2021 | |||||||
| 23.1 | Consent of Ernst & Young, LLP. | X | ||||||||||
| 23.2 | Consent of Latham & Watkins LLC (included in Exhibit 5.1). | X | ||||||||||
| 23.3 | Consent of Frost & Sullivan. | X | ||||||||||
| 24.1 | Power of Attorney (included on signature page). | X | ||||||||||
| 101.INS | Inline XBRL Instance Document | X | ||||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X | ||||||||||
| (b) | Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. |
Item 17. |
Undertakings. |
| (1) | For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
| (2) | For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
FIGS, INC. | ||
| By: | /s/ Catherine Spear | |
| Name: | Catherine Spear | |
| Title: | Co-Chief Executive Officer and Director | |
| Signature |
Title |
Date | ||
| /s/ Heather Hasson Heather Hasson |
Co-Chief Executive Officer and Director(Co-Principal Executive Officer) |
September 13, 2021 | ||
| /s/ Catherine Spear Catherine Spear |
Co-Chief Executive Officer and Director( Co-Principal Executive Officer |
September 13, 2021 | ||
| /s/ Jeffrey D. Lawrence Jeffrey D. Lawrence |
Chief Financial Officer ( Principal Financial and Accounting Officer |
September 13, 2021 | ||
| /s/ J. Martin Willhite J. Martin Willhite |
Director |
September 13, 2021 | ||
| /s/ Sheila Antrum Sheila Antrum |
Director |
September 13, 2021 | ||
| /s/ Michael Soenen Michael Soenen |
Director |
September 13, 2021 | ||
Exhibit 1.1
FIGS, Inc.
Class A Common Stock
Underwriting Agreement
September [•], 2021
Goldman Sachs & Co. LLC,
Morgan Stanley & Co. LLC,
As representatives (the “Representatives”) of the several Underwriters
named in Schedule I hereto,
| c/o | Goldman Sachs & Co. LLC |
200 West Street
New York, New York 10282
| c/o | Morgan Stanley & Co. LLC |
1585 Broadway
New York, New York 10036
Ladies and Gentlemen:
The stockholders named in Schedule II hereto (the “Selling Stockholders”) of FIGS, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Class A common stock, par value $0.0001 per share (“Class A Common Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.” The shares of Class A Common Stock of the Company and the shares of Class B common stock, par value $0.0001 per share, of the Company, to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Stock.” In the event that the Company has a single subsidiary or does not have any subsidiaries, then all references herein to “subsidiaries” of the Company shall be deemed to refer to such single subsidiary or to the Company, respectively, mutatis mutandis.
1. (a) The Company represents and warrants to, and agrees with, each of the Underwriters that:
(i) A registration statement on Form S-1 (File No. 333-[•]) (the “Initial Registration Statement”) in respect of the Shares has been filed with the Securities and Exchange Commission (the “Commission”); the Initial Registration Statement and any post-effective amendment thereto, each in the form heretofore delivered to you, have been declared effective by the Commission in such form; other than a registration statement, if any, increasing the size of the offering (a “Rule 462(b) Registration Statement”), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Act”), which became effective upon filing, no other document with respect to the Initial Registration
Statement has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A of the Act has been initiated or, to the Company’s knowledge, threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule 424(a) under the Act is hereinafter called a “Preliminary Prospectus”; the various parts of the Initial Registration Statement and the Rule 462(b) Registration Statement, if any, including all exhibits thereto and including the information contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section 5(a) hereof and deemed by virtue of Rule 430A under the Act to be part of the Initial Registration Statement at the time it was declared effective, each as amended at the time such part of the Initial Registration Statement became effective or such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively called the “Registration Statement”; the Preliminary Prospectus relating to the Shares that was included in the Registration Statement immediately prior to the Applicable Time (as defined in Section 1(a)(iii) hereof) is hereinafter called the “Pricing Prospectus”; such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is hereinafter called the “Prospectus”; any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Act or Rule 163B under the Act is hereinafter called a “Testing-the-Waters Communication”; any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a “Written Testing-the-Waters Communication”; and any “issuer free writing prospectus” as defined in Rule 433 under the Act relating to the Shares is hereinafter called an “Issuer Free Writing Prospectus”);
(ii) (A) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission, and (B) each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section 9(c) of this Agreement);
(iii) For the purposes of this Agreement, the “Applicable Time” is [•] p.m., New York City time, on the date of this Agreement; the Pricing Prospectus, as supplemented by the information listed on Schedule III(c) hereto, taken together (collectively, the “Pricing Disclosure Package”), as of the Applicable Time, did not, and as of each Time of Delivery (as defined in Section 4(a) of this Agreement) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Written Testing-the-Waters Communication does not conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus, and each Issuer Free Writing Prospectus and each Written Testing-the-Waters Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the Applicable Time, did not, and as of each Time of Delivery, will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements or omissions made in reliance upon and in conformity with the Underwriter Information;
2
(iv) No documents were filed with the Commission since the Commission’s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule III(b) hereto;
(v) The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement, as of the applicable filing date as to the Prospectus and any amendment or supplement thereto and as of each Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information;
(vi) Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included in the Pricing Prospectus, (i) sustained any material loss or material interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or (ii) entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the Pricing Disclosure Package, there has not been (x) any change in the capital stock (other than as a result of (i) the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary course of business pursuant to the Company’s equity plans that are described in the Pricing Disclosure Package and the Prospectus or (ii) the issuance, if any, of stock upon conversion of Company securities as described in the Pricing Disclosure Package and the Prospectus) or long-term debt of the Company or any of its subsidiaries or (y) any Material Adverse Effect; as used in this Agreement, “Material Adverse Effect” shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i) the business, properties, general affairs, management, financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (ii) the ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus;
(vii) The Company and its subsidiaries do not own any real property. The Company has good and marketable title to all material personal property (other than with respect to intellectual property which is addressed exclusively in subsection (xxvi) below) owned by them, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries;
3
(viii) Each of the Company and each of its subsidiaries has been (i) duly organized and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Prospectus, and (ii) duly qualified as a foreign corporation or other business entity for the transaction of business and is in good standing (where such concept exists) under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and each subsidiary of the Company required to be identified has been listed in the Registration Statement;
(ix) The Company has an authorized capitalization as set forth in the Pricing Prospectus and all of the issued shares of capital stock of the Company, including the Shares to be sold by the Selling Stockholders, have been duly and validly authorized and issued and are fully paid and non-assessable (or, in the case of Shares to be sold by the Selling Stockholders that will be issued following the exercise of currently outstanding options under the Company’s Amended 2016 Equity Incentive Plan, such Shares upon issuance will be duly and validly issued and fully paid and non-assessable) and conform in all material respects to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus;
(x) [Omitted;]
(xi) The compliance by the Company with this Agreement and the consummation of the transactions contemplated in this Agreement and the Pricing Disclosure Package will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A) any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (B) the certificate of incorporation or by-laws (or other applicable organizational document) of the Company or any of its subsidiaries, or (C) any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (A) and (C) for such defaults, breaches or violations that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority (“FINRA”) of the underwriting terms and arrangements, the approval for listing the Shares on the New York Stock Exchange (the “Exchange”) and such consents, approvals, authorizations, orders, registrations or qualifications as may have been obtained or as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Underwriters;
4
(xii) Neither the Company nor any of its subsidiaries is (i) in violation of its certificate of incorporation or by-laws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, or (iii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii) and (iii), for such violations or defaults as would not, individually or in the aggregate, have a Material Adverse Effect;
(xiii) The statements set forth in the Pricing Prospectus and the Prospectus under the caption “Description of Capital Stock,” insofar as they purport to constitute a summary of the terms of the Stock and under the caption “Underwriting,” insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects, and the statements set forth in the Pricing Prospectus and the Prospectus under the caption “Material U.S. Federal Income Tax Consequences to Non-U.S. Holders,” insofar as they purport to constitute summaries of U.S. federal income tax law and regulations or legal conclusions with respect thereto, constitute accurate summaries of the matters described therein in all material respects;
(xiv) Other than as set forth in the Pricing Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries or, to the Company’s knowledge, any officer or director of the Company is a party or of which any property or assets of the Company or any of its subsidiaries or, to the Company’s knowledge, any officer or director of the Company is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in the aggregate reasonably be expected to have a Material Adverse Effect; and, to the Company’s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others;
(xv) The Company is not required to register as an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”);
(xvi) At the time of filing the Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405 under the Act;
(xvii) Ernst & Young LLP, who have certified certain financial statements of the Company and its subsidiaries, are independent public accountants as required by the Act and the rules and regulations of the Commission thereunder;
(xviii) The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that (i) has been designed to comply with the requirements of the Exchange Act, (ii) has been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide
5
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”) and (iii) is designed to provide reasonable assurance that (A) transactions are executed in accordance with management’s general or specific authorization, (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (C) access to assets is permitted only in accordance with management’s general or specific authorization and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and the Company’s internal control over financial reporting is effective. The Company is not aware of any material weaknesses in its internal control over financial reporting; provided, however, that this subsection does not require that the Company comply with Section 404 of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder (the “Sarbanes-Oxley Act”) as of an earlier date than it would otherwise be required to so comply under applicable law;
(xix) Since the date of the latest audited financial statements included in the Pricing Prospectus, there has been no change in the Company’s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting;
(xx) The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective;
(xxi) This Agreement has been duly authorized, executed and delivered by the Company;
(xxii) Neither the Company nor any of its subsidiaries, nor any director or officer of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, employee, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively, “Anti-Corruption Laws”); the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein;
(xxiii) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various jurisdictions in which the
6
Company and its subsidiaries conduct business (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened;
(xxiv) Neither the Company nor any of its subsidiaries, nor any director or officer of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, employee or affiliate of the Company or any of its subsidiaries is, or is owned or controlled by one or more individuals or entities that are, (i) currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person,” the European Union, Her Majesty’s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, “Sanctions”), or (ii) located, organized or resident in a country or territory that is the subject or target of Sanctions (a “Sanctioned Jurisdiction”). For the past five years, the Company and its subsidiaries have not engaged in, are not now engaged in, and will not engage in any dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction;
(xxv) The financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position of the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its subsidiaries for the periods specified; said financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in all material respects and in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the Pricing Prospectus and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Prospectus or the Prospectus under the Act or the rules and regulations promulgated thereunder. All disclosures contained in the Registration Statement, the Pricing Prospectus and the Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Act, to the extent applicable;
(xxvi) Except as would not, individually or in the aggregate, have a Material Adverse Effect, the Company and each of its subsidiaries (i) own or otherwise possess adequate rights to use all patents, trademarks, service marks, trade names, domain names, copyrights, know-how, software, systems and technology (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures and other intellectual property) necessary for the conduct of their respective businesses, (ii) do not, through the conduct of their respective businesses, infringe or violate any such right of others and (iii) have not received any written notice of any claim of infringement or violation of any such rights of others;
7
(xxvii) Except as would not, individually or in the aggregate, have a Material Adverse Effect, the Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, to the knowledge of the Company, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have adopted and maintain commercially reasonable controls, policies, procedures and safeguards designed to maintain and protect their confidential information and the integrity, continuous operation, redundancy and security of their IT Systems and data (including information relating to an identifiable natural person and any other personal or personally identifiable data or information (“Personal Data”)) used in connection with their businesses, and, except as would not, individually or in the aggregate, have a Material Adverse Effect there have been no breaches, violations, outages or unauthorized uses of or accesses to same. The Company and its subsidiaries are presently in compliance and have at all times complied in all respects with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, and Personal Data, the protection of such IT Systems, and Personal Data from unauthorized use, access, misappropriation or modification, direct marketing or communications by telephone or text messages and consumer protection (collectively, “Privacy Requirements”) except for any of the foregoing that would not, individually or in the aggregate, have a Material Adverse Effect. The Company has at all times made all disclosures to users or customers required by Privacy Requirements, and no such disclosures or public statements of the Company have been inaccurate or misleading in any material respect. The Company (i) has not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Privacy Requirements, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is not currently involved in any investigation, remediation or other corrective action required pursuant to any Privacy Requirements; and (iii) is not a party to any settlement, judgment, order or decree that imposes any obligation or liability under any Privacy Requirements;
(xxviii) Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in each of the Registration Statement, the Pricing Prospectus and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects;
(xxix) There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including Section 402 related to loans;
(xxx) Neither the Company nor any of its affiliates has taken or will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of the Shares;
(xxxi) The Company and each of its subsidiaries have such permits, licenses, approvals, consents, franchises, certificates of need and other approvals or authorizations of governmental or regulatory authorities (“Permits”) as are necessary under applicable law to own their respective properties and conduct their respective businesses in the manner described in the Registration Statement, the Pricing Prospectus and the
8
Prospectus, except for any of the foregoing that would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received notice of any proceedings related to the revocation or modification of any such Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect;
(xxxii) From the time of initial confidential submission of a registration statement relating to the Shares with the Commission through the date hereof, the Company has been and is an “emerging growth company” as defined in Section 2(a)(19) of the Act (an “Emerging Growth Company”);
(xxxiii) The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
(xxxiv) No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers or contractors that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
(xxxv) (A) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are, in the Company’s judgment, commercially reasonable and customary in the businesses in which they are engaged; (B) neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and (C) neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect;
(xxxvi) The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement, or have requested extensions thereof, and have paid all taxes required to be paid thereon (except for where the failure to file or pay would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or except as currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company or its applicable subsidiary), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries that has had (nor has the Company nor any of its subsidiaries received written notice or have knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a Material Adverse Effect; and
9
(xxxvii) On or after the Applicable Time there will be no debt securities issued or guaranteed by the Company that are rated by any “nationally recognized statistical rating organization,” as that term is defined by the Commission for purposes of Rule 436(g)(2)under the Act.
(b) Each of the Selling Stockholders, severally and not jointly, represents and warrants to, and agrees with, each of the Underwriters and the Company that:
(i) All consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Stockholder of this Agreement and for the sale and delivery of the Shares to be sold by such Selling Stockholder to the Underwriters hereunder, have been obtained, except for the registration under the Act of the Shares and such consents, approvals, authorizations and orders as may be required under state securities or Blue Sky laws, the rules and regulations of FINRA or the approval for listing on the Exchange; and such Selling Stockholder has full right, power and authority to enter into this Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling Stockholder to the Underwriters hereunder;
(ii) The sale of the Shares to be sold by such Selling Stockholder to the Underwriters hereunder, the compliance by such Selling Stockholder with this Agreement, and the consummation of the transactions herein contemplated will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any statute, indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which such Selling Stockholder is a party or by which such Selling Stockholder is bound or to which any of the property or assets of such Selling Stockholder is subject, nor will such action result in any violation of (A) in the case of a Selling Stockholder that is a legal entity (a “Corporate Selling Stockholder”), the provisions of such Selling Stockholder’s formation and organizational documents (including, but not limited to, Certificates of Incorporation, By-laws, Certificates of Formation, Limited Liability Company Agreements and Partnership Agreements), as applicable, or (B) in the case of any Selling Stockholder, whether or not a Corporate Selling Stockholder, any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over such Selling Stockholder or any of its subsidiaries (in the case of any Corporate Selling Stockholder, as applicable) or any property or assets of such Selling Stockholder, except, in each case, for any such conflict, breach, violation or default that would not, individually or in the aggregate, affect the validity of the Shares to be sold by such Selling Stockholder to the Underwriters hereunder or reasonably be expected to materially impair the ability of such Selling Stockholder to consummate the transactions contemplated by this Agreement; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental body or agency is required for the performance by such Selling Stockholder of its obligations under this Agreement and the consummation by such Selling Stockholder of the transactions contemplated by this Agreement in connection with the Shares to be sold by such Selling Stockholder to the Underwriters hereunder, except the registration under the Act of the Shares, the approval by FINRA of the underwriting terms and arrangements, the approval for listing on the New York Stock Exchange and such consents, approvals, authorizations, orders, registrations or qualifications (x) as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Underwriters, (y) that have already been obtained or (z) such that, if not obtained, would not, individually or in the aggregate, affect the validity of the Shares to be sold by such Selling Stockholder to the Underwriters hereunder or reasonably be expected to materially impair the ability of such Selling Stockholder to consummate the transactions contemplated by this Agreement;
10
(iii) Such Selling Stockholder has (or, in the case of Shares to be sold by such Selling Stockholder that will be issued following the exercise of currently outstanding options under the Company’s Amended 2016 Equity Incentive Plan, such Selling Stockholder will have upon issuance of such Shares), and immediately prior to each Time of Delivery (as defined in Section 4 hereof) such Selling Stockholder will have, good and valid title to, or a valid “security entitlement” within the meaning of Section 8-501 of the New York Uniform Commercial Code in respect of, the Shares to be sold by such Selling Stockholder to the Underwriters hereunder at such Time of Delivery, free and clear of all liens, encumbrances, equities or claims; and, upon delivery of such Shares and payment therefor pursuant hereto, good and valid title to such Shares, free and clear of all liens, encumbrances, equities or claims, will pass to the several Underwriters;
(iv) On or prior to the date of the Pricing Prospectus, such Selling Stockholder has executed and delivered to the Underwriters an agreement substantially in the form of Annex I hereto.
(v) Such Selling Stockholder has not taken and will not take, directly or indirectly, any action that is designed to or that has constituted or would reasonably be expected to cause or result in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares;
(vi) The Registration Statement and Preliminary Prospectus did, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus will, when they become effective or are filed with the Commission, as the case may be, not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; provided that such representations and warranties set forth in this clause (vi) apply, with respect to a Selling Stockholder, only to statements or omissions made in the Registration Statement, the Preliminary Prospectus, the Prospectus and any further amendments or supplements to the Registration Statement, the Preliminary Prospectus and the Prospectus that are made in reliance upon and in conformity with written information furnished to the Company by such Selling Stockholder expressly for use therein; provided, further, that it is agreed that such information furnished by such Selling Stockholder to the Company consists only of (A) the legal name, address and the number of Shares owned by such Selling Stockholder before and after the offering, (B) any biographical information provided by such Selling Stockholder with regard to representatives of such Selling Stockholder that are members of the board of directors of the Company and (C) the other information with respect to such Selling Stockholder (excluding percentages) which appear in the table (and corresponding footnotes) under the caption “Principal and Selling Stockholders” (such information in the foregoing clauses (A), (B) and (C) with respect to such Selling Stockholder, collectively, the “Selling Stockholder Information”);
(vii) In order to document the Underwriters’ compliance with the reporting and withholding provisions of the Tax Equity and Fiscal Responsibility Act of 1982 with respect to the transactions herein contemplated, such Selling Stockholder will deliver to you prior to or at the First Time of Delivery (as defined in Section 4 hereof) a properly completed and executed United States Treasury Department Form W-9 (or other applicable form or statement specified by Treasury Department regulations in lieu thereof);
11
(viii) (A) Neither such Selling Stockholder nor (B) in the case of a Corporate Selling Stockholder, any of such Selling Stockholder’s subsidiaries nor any director, officer or employee of such Selling Stockholder or any of its subsidiaries nor (C) to the knowledge of such Selling Stockholder, any agent, affiliate or other person associated with or acting on behalf of such Selling Stockholder or (in the case of a Corporate Selling Stockholder) any of its subsidiaries has (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Anti-Corruption Laws; in the case of a Corporate Selling Stockholder, such Selling Stockholder and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; neither such Selling Stockholder nor (in the case of a Corporate Selling Stockholder) any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws;
(ix) In the case of a Corporate Selling Stockholder, the operations of such Selling Stockholders and its subsidiaries are and have been conducted at all times in compliance with the Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Selling Stockholder or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of such Selling Stockholder, threatened; in the case of a Selling Stockholder who is a trustee or a natural person, such Selling Stockholder is and has acted at all times in compliance with applicable Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Selling Stockholder with respect to any applicable Money Laundering Laws is pending or, to the knowledge of such Selling Stockholder, threatened;
(x) (A) In the case of a Corporate Selling Stockholder, neither such Selling Stockholder nor any of its subsidiaries, nor any director, officer or employee of such Selling Stockholder or any of its subsidiaries, nor, to the knowledge of such Selling Stockholder, any agent, affiliate or other person associated with or acting on behalf of such Selling Stockholder or any of its subsidiaries is, or is owned or controlled by one or more individuals or entities that are, (i) currently the subject or the target of any Sanctions, (ii) located, organized or resident in a Sanctioned Jurisdiction; and (B) such Selling Stockholder will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, (i) to fund or facilitate any activities of or business with any person, or in any country or territory, that, at the time of such funding, is the subject or the target of Sanctions or (ii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; neither such Selling Stockholder nor (in the case of a Corporate Selling Stockholder) any of its subsidiaries is engaged in, will engage in or has engaged in, any dealings or transactions with or involving
12
any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; in the case of a Corporate Selling Stockholder, such Selling Stockholder and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions;
(xi) Such Selling Stockholder is not prompted by any information concerning the Company or any of its subsidiaries that is not disclosed in the Pricing Prospectus to sell its Shares pursuant to this Agreement; and
(xii) If a Selling Stockholder is a Corporate Selling Stockholder, such Selling Stockholder has been duly organized and is validly existing and in good standing, in each case, under the laws of its respective jurisdiction.
2. Subject to the terms and conditions herein set forth, (a) each of the Selling Stockholders agrees, severally and not jointly, to sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from each of the Selling Stockholders, at a purchase price per share of $[•], the number of Firm Shares (to be adjusted by you so as to eliminate fractional shares) determined by multiplying the aggregate number of Firm Shares to be sold by each of the Selling Stockholders as set forth opposite their respective names in Schedule II hereto by a fraction, the numerator of which is the aggregate number of Firm Shares to be purchased by such Underwriter as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the aggregate number of Firm Shares to be purchased by all of the Underwriters from all of the Selling Stockholders hereunder and (b) in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, each of the Selling Stockholders, severally and not jointly, as and to the extent indicated in Schedule II attached hereto, agrees to sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from each of the Selling Stockholders, at the purchase price per share set forth in clause (a) of this Section 2 (provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such number of Optional Shares by a fraction the numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder.
The Selling Stockholders, as and to the extent indicated in Schedule II hereto, hereby grant, severally and not jointly, to the Underwriters the right to purchase at their election up to [•] Optional Shares, at the purchase price per share set forth in the paragraph above (provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares). Any such election to purchase Optional Shares shall be made in proportion to the number of Optional Shares to be sold by each Selling Stockholder. Any such election to purchase Optional Shares may be exercised only by written notice from you to the Company and the Selling Stockholders, given within a period of 30 calendar days after the date of this Agreement and setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by you but in no event earlier than the First Time of Delivery or, unless you and the Company and the Selling Stockholders otherwise agree in writing, earlier than two or later than ten business days after the date of such notice.
13
3. Upon the authorization by you of the release of the Shares, the several Underwriters propose to offer the Shares for sale upon the terms and conditions set forth in the Pricing Disclosure Package and the Prospectus.
4. (a) The Shares to be purchased by each Underwriter hereunder, in definitive or book-entry form, and in such authorized denominations and registered in such names as the Representatives may request upon at least forty-eight hours’ prior notice to the Company and the Selling Stockholders shall be delivered by or on behalf of the Selling Stockholders to the Representatives, through the facilities of the Depository Trust Company (“DTC”), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the accounts specified by the Company and the Selling Stockholders to the Representatives at least forty-eight hours in advance. The Company and the Selling Stockholders will cause the certificates, if any, representing the Shares to be made available for checking and packaging at least twenty-four hours prior to the Time of Delivery (as defined below) with respect thereto at the office of DTC or its designated custodian (the “Designated Office”). The time and date of such delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m., New York time, on September [•], 2021 or such other time and date as the Representatives, the Company and the Selling Stockholders may agree upon in writing, and, with respect to the Optional Shares, 9:30 a.m., New York time, on the date specified by the Representatives in each written notice given by the Representatives of the Underwriters’ election to purchase such Optional Shares, or such other time and date as the Representatives, the Company and the Selling Stockholders may agree upon in writing. Such time and date for delivery of the Firm Shares is herein called the “First Time of Delivery,” each such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the “Second Time of Delivery,” and each such time and date for delivery is herein called a “Time of Delivery.”
(b) The documents to be delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section 8(l) hereof will be delivered at the offices of Cooley LLP: 101 California Street, 5th Floor, San Francisco, California 94111 (the “Closing Location”), and the Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at the Closing Location at 10:00 a.m., New York City time, on the New York Business Day next preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section 4, “New York Business Day” shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York are generally authorized or obligated by law or executive order to close.
5. The Company agrees with each of the Underwriters:
(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act not later than the Commission’s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule 430A(a)(3) under the Act; to make no further amendment or any supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any amendment to the
14
Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all material required to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order;
(b) Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and sale under the securities laws of such jurisdictions as you may reasonably request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation (where not otherwise required) or to file a general consent to service of process in any jurisdiction (where not otherwise required);
(c) Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by you, the Company and the Selling Stockholders) and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order to comply with the Act, to notify you and upon your request to prepare and furnish without charge to each Underwriter and to any dealer in securities (whose name and address the Underwriters shall furnish to the Company) as many written and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Act;
(d) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission’s Electronic Data Gathering Analysis and Retrieval System (“EDGAR”)), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section 11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158);
15
(e) (i) During the period beginning from the date hereof and continuing to and including November 22, 2021 (the “Lock-Up Period”), not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing in clause (i) or (ii), whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC; provided, however that the forgoing restrictions shall not apply to (1) the Shares to be sold hereunder, (2) any shares of Stock or any securities or other awards (including without limitation options, restricted stock or restricted stock units) convertible into, exercisable for, or that represent the right to receive, shares of Stock pursuant to any stock option plan, incentive plan or stock purchase plan of the Company (collectively, “Company Stock Plans”) or otherwise in equity compensation arrangements described in the Registration Statement and the Prospectus or any shares of Stock issuable upon the exercise, conversion or settlement of such awards, provided that any directors or officers who are the recipient thereof have provided to the Representatives a signed lock-up letter substantially in the form of Annex I hereto, (3) the issuance by the Company of shares of its Class A common stock upon the conversion of shares of its Class B common stock, (4) the filing by the Company of any registration statement on Form S-8 or a successor form thereto relating to any Company Stock Plan described in the Registration Statement and the Prospectus or any assumed employee benefit plan contemplated by clause (5), and (5) any shares of Stock or any securities convertible into or exchangeable for, or that represent the right to receive, shares of Stock issued in connection with any joint venture, commercial or collaborative relationship or the acquisition or license by the Company of the securities, businesses, property or other assets of another person or entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition, provided that in the case of clause (5), the aggregate number of shares that the Company may sell or issue or agree to sell or issue pursuant to clause (5), (x) shall not exceed 5.0% of the total number of shares of Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement) and (y) the recipients thereof provide to the Representatives a signed lock-up letter substantially in the form of Annex I hereto;
(ii) [Omitted;]
(iii) To not instruct its counsel or the transfer agent to authorize or facilitate the transfer of any Shares subject to a signed lock-up letter with the Underwriters substantially in the form of Annex I hereto until, in respect of any particular securityholder, the earlier to occur of (A) the expiration of the Lock-Up Period or (B) the expiration of any similar arrangement entered into by such securityholder with the Representatives; to direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such existing “lock-up,” “market stand-off,” “holdback” or similar provisions of such agreements for the duration of the periods contemplated in the preceding clause; and not to release or otherwise grant any waiver of such provisions in such agreements during such periods without the prior written consent of the Representatives, on behalf of the Underwriters;
16
(f) During a period of three years from the effective date of the Registration Statement, for so long as the Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act, to furnish to its stockholders as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders’ equity and cash flows of the Company and its consolidated subsidiaries certified by independent public accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail; provided, however, that the Company may satisfy the requirements of this Section 5(f) by filing such information through EDGAR;
(g) During a period of three years from the effective date of the Registration Statement, to furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to you (i) as soon as they are available, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed; and (ii) such additional information concerning the business and financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its subsidiaries are consolidated in reports furnished to its stockholders generally or to the Commission) provided, however, that the Company may satisfy the requirements of this Section 5(g) by filing such information through EDGAR;
(h) [Omitted;]
(i) To use its best efforts to list for trading the Shares on the Exchange;
(j) [Omitted;]
(k) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule 462(b) Registration Statement with the Commission in compliance with Rule 462(b) by 10:00 p.m., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 3a(c) of the Commission’s Informal and Other Procedures (16 CFR 202.3a);
(l) Upon request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company’s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the on-line offering of the Shares (the “License”); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred;
(m) [Omitted;]
17
(n) To promptly notify you if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of the Shares within the meaning of the Act and (ii) the last Time of Delivery.
6. (a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a “free writing prospectus” as defined in Rule 405 under the Act; each Selling Stockholder represents and agrees that, without the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus; and each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of which has been consented to by the Company and the Representatives is listed on Schedule III(a) hereto;
(b) The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending;
(c) The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or Written Testing-the-Waters Communication prepared or authorized by it any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written Testing-the-Waters Communication prepared or authorized by it would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written Testing-the-Waters Communication or other document which will correct such conflict, statement or omission; provided, however, that this representation and warranty shall not apply to any statements or omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with the Underwriter Information;
(d) The Company represents and agrees that (i) it has not engaged in, or authorized any other person to engage in, any Testing-the-Waters Communications, other than Testing-the-Waters Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act; and (ii) it has not distributed, or authorized any other person to distribute, any Written Testing-the-Waters Communication, other than those distributed with the prior consent of the Representatives that are listed on Schedule III(d) hereto; and the Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in Testing-the-Waters Communications; and
(e) Each Underwriter represents and agrees that any Testing-the-Waters Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Act.
18
7. The Company and each of the Selling Stockholders covenant and agree with one another and with the several Underwriters that (a) the Company will pay or cause to be paid the following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration Statement, any Preliminary Prospectus, any Written Testing-the-Waters Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii) the cost of printing or producing any agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii) reasonable and documented expenses in connection with the qualification of the Shares for offering and sale under state securities laws as provided in Section 5(b) hereof, including the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey; (iv) all fees and expenses in connection with listing the Shares on the Exchange; (v) reasonable and documented filing fees incident to, and the fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares; (vi) the cost of preparing stock certificates, if applicable; (vii) the cost and charges of any transfer agent or registrar; and (viii) all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section; provided that the amount payable by the Company pursuant to subsections (iii) and (v) for fees and disbursements of counsel shall not exceed $40,000 in the aggregate and (b) such Selling Stockholder will pay or cause to be paid all costs and expenses incident to the performance of such Selling Stockholder’s obligations hereunder which are not otherwise specifically provided for in this Section, including (i) any fees and expenses of counsel for such Selling Stockholder and (ii) all expenses and taxes incident to the sale and delivery of the Shares to be sold by such Selling Stockholder to the Underwriters hereunder. It is understood, however, that the Company shall bear, and the Selling Stockholders shall not be required to pay or to reimburse the Company for, the cost of any other matters not directly relating to the sale and purchase of the Shares pursuant to this Agreement, and that, except as provided in this Section, and Sections 9 and 12 hereof, the Underwriters will pay all of their own costs and expenses, including their own lodging, travel and meal expenses (including meal expenses for potential investors) in connection with any roadshow, the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and any advertising expenses connected with any offers they may make, and the Underwriters will be responsible for 50% of the cost of any chartered plane or other transportation chartered in connection with any “roadshow” presentation to investors undertaken in connection with the offering of the Shares hereunder.
8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each Time of Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company and the Selling Stockholders herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition that the Company and the Selling Stockholders shall have performed all of its and their obligations hereunder theretofore to be performed, and the following additional conditions:
(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section 5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433; if the Company has elected to rely upon Rule 462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 p.m., Washington, D.C. time, on the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part
19
thereof shall have been issued and no proceeding for that purpose or pursuant to Section 8A of the Act shall have been initiated or threatened by the Commission no stop order suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction;
(b) Cooley LLP, counsel for the Underwriters, shall have furnished to you such written opinion or opinions and negative assurance letter or letters, dated such Time of Delivery, in form and substance satisfactory to you, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters;
(c) Latham & Watkins LLP, counsel for the Company, shall have furnished to you their written opinion and negative assurance letter, dated such Time of Delivery, in form and substance reasonably satisfactory to you;
(d) The respective counsel for each of the Selling Stockholders, as indicated in Schedule II hereto, each shall have furnished to you their written opinion with respect to each of the Selling Stockholders for whom they are acting as counsel, dated such Time of Delivery, in form and substance reasonably satisfactory to you;
(e) On the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New York City time, on the effective date of any post-effective amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, Ernst & Young LLP shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to you;
(f) The Company shall have delivered to the Representatives on the date of the Prospectus at a time prior to the execution of this Agreement and at such Time of Delivery a certificate of the Chief Financial Officer of the Company, in form and substance reasonably satisfactory to you;
(g) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii) since the respective dates as of which information is given in the Pricing Disclosure Package there shall not have been any change in the capital stock (other than as a result of the exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company’s equity plans that are described in the Pricing Prospectus) or long-term debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting (x) the business, properties, general affairs, management, financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Disclosure Package, or (y) the ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated in the Pricing Disclosure Package and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Disclosure Package and the Prospectus;
20
(h) On or after the Applicable Time there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the Exchange or the NASDAQ Global Market; (ii) a suspension or material limitation in trading in the Company’s securities on the Exchange; (iii) a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;
(i) The Shares to be sold at such Time of Delivery shall have been duly listed on the Exchange;
(j) The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from (i) each officer and director and (ii) certain security holders of the Company, in each case substantially to the effect set forth in Annex I hereto;
(k) The Company shall have complied with the provisions of Section 5(c) hereof with respect to the furnishing of prospectuses on the New York Business Day next succeeding the date of this Agreement; and
(l) The Company and the Selling Stockholders shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the Company, officers of the Corporate Selling Stockholders, and of the remaining Selling Stockholders, respectively, satisfactory to you as to the accuracy of the representations and warranties of the Company and the Selling Stockholders, respectively, herein at and as of such Time of Delivery, as to the performance by the Company and the Selling Stockholders of all of their respective obligations hereunder to be performed at or prior to such Time of Delivery, as to such other matters as you may reasonably request, and the Company shall have furnished or caused to be furnished certificates as to the matters set forth in subsections (a) and (g) of this Section 8 and as to such other matters as you may reasonably request.
(m) The Company and each Corporate Selling Stockholder shall have delivered to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company and each Corporate Selling Stockholder shall have undertaken to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the foregoing Certification.
9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any “roadshow” as defined in Rule 433(h) under the Act (a “roadshow”), any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Act or any
21
Testing-the-Waters Communication prepared or authorized by the Company, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information.
(b) Each of the Selling Stockholders listed in Schedule II hereto, severally and not jointly, will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any roadshow or any Testing-the-Waters Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto or any Issuer Free Writing Prospectus, or any roadshow or any Testing-the-Waters Communication, in reliance upon and in conformity with the Selling Stockholder Information of such Selling Stockholder; and will severally and not jointly reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that such Selling Stockholder shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus or any amendment or supplement thereto or any Issuer Free Writing Prospectus in reliance upon and in conformity with the Underwriter Information. Notwithstanding anything to the contrary in this Section 9, the several liability of each Selling Stockholder under this Section 9(b) shall in no event exceed the amount of such Selling Stockholder’s net proceeds (after deducting underwriting discounts and commissions but before deducting any other expenses) from its sale of the Shares under this Agreement (the “Selling Stockholder Proceeds”).
(c) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company and each Selling Stockholder against any losses, claims, damages or liabilities to which the Company or such Selling Stockholder may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow, or any Testing-the-Waters Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to
22
the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow, or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company and each Selling Stockholder for any legal or other expenses reasonably incurred by the Company or such Selling Stockholder in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, “Underwriter Information” shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the information contained in the first, second, fifth, sixth, eight, ninth and tenth sentences of the tenth paragraph under the caption “Underwriting.”
(d) Promptly after receipt by an indemnified party under subsection (a), (b) or (c) of this Section 9 of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of this Section 9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.
23
(e) If the indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a), (b) or (c) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling Stockholders on the one hand and the Underwriters on the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company and the Selling Stockholders on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling Stockholders on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company and the Selling Stockholders bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Selling Stockholder on the one hand or the Underwriters on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company, each of the Selling Stockholders and the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (e) were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (e). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (e) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (e), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations in this subsection (e) to contribute are several in proportion to their respective underwriting obligations and not joint. Notwithstanding anything to the contrary in this Section 9, the liability of each Selling Stockholder under this Section 9(e) shall in no event exceed its Selling Stockholder Proceeds; provided, however, in no event shall any Selling Stockholder be required to contribute pursuant to this subsection (e) any amount in excess of the amount by which the Selling Stockholder Proceeds received by such Selling Stockholder from the sale of the Shares exceeds the damages that such Selling Stockholder would have otherwise been required to pay under subsection (b) above by reason of an untrue or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with the Selling Stockholder Information.
(f) The obligations of the Company and the Selling Stockholders under this Section 9 shall be in addition to any liability which the Company and the Selling Stockholders may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any Underwriter; and the obligations
24
of the Underwriters under this Section 9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company) and to each person, if any, who controls the Company or any Selling Stockholder within the meaning of the Act.
10. (a) If any Underwriter shall default in its obligation to purchase the Shares that it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If within thirty-six hours after such default by any Underwriter you do not arrange for the purchase of such Shares, then the Company and the Selling Stockholders shall be entitled to a further period of thirty-six hours within which to procure another party or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the Company and the Selling Stockholders that you have so arranged for the purchase of such Shares, or the Company or a Selling Stockholder notifies you that it has so arranged for the purchase of such Shares, you or the Company or the Selling Stockholders shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with respect to such Shares.
(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you, the Company and the Selling Stockholders as provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased does not exceed one-eleventh of the aggregate number of all the Shares to be purchased at such Time of Delivery, then the Selling Stockholders shall have the right to require each non-defaulting Underwriter to purchase the number of Shares which such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each non-defaulting Underwriter to purchase its pro rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default.
(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you, the Company and the Selling Stockholders as provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased exceeds one-eleventh of the aggregate number of all of the Shares to be purchased at such Time of Delivery, or if the Selling Stockholders shall not exercise the right described in subsection (b) above to require non-defaulting Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to a Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company and the Selling Stockholders to sell the Optional Shares) shall thereupon terminate, without liability on the part of any non-defaulting Underwriter, the Company or the Selling Stockholders, except for the expenses to be borne by the Company, the Selling Stockholders and the Underwriters as provided in Section 7 hereof and the indemnity and contribution agreements in Section 9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default.
25
11. The respective indemnities, rights of contribution, agreements, representations, warranties and other statements of the Company, the Selling Stockholders and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any director, officer, employee, affiliate or controlling person of any Underwriter, or the Company, or any of the Selling Stockholders, or any officer or director or controlling person of the Company, or any controlling person of any Selling Stockholder, and shall survive delivery of and payment for the Shares.
12. If this Agreement shall be terminated pursuant to Section 10 hereof, neither the Company nor the Selling Stockholders shall then be under any liability to any Underwriter except as provided in Sections 7 and 9 hereof; but, if for any other reason any Shares are not delivered by or on behalf of the Selling Stockholders as provided herein, or the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, each of the Selling Stockholders pro rata (based on the number of Shares to be sold by each Selling Stockholder hereunder) will reimburse the Underwriters through you for all reasonably incurred and documented out-of-pocket expenses approved in writing by you, including documented fees and disbursements of counsel, reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company and the Selling Stockholders shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9 hereof.
13. In all dealings hereunder, the Representatives shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by the Representatives on behalf of the Underwriters.
In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company and the Selling Stockholders, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.
All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to the Representatives: Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attention: Registration Department and Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; if to any Selling Stockholder shall be delivered or sent by mail, telex or facsimile transmission to counsel for such Selling Stockholder at its address set forth in Schedule II hereto; if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth on the cover of the Registration Statement, Attention: Secretary; provided, however, that any notice to an Underwriter pursuant to Section 9(d) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Underwriter at its address set forth in its Underwriters’ Questionnaire or telex constituting such Questionnaire, which address will be supplied to the Company or the Selling Stockholders by you on request; provided, however, that notices under subsection 5(e) shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to you as the representatives at Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control Room and Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department. Any such statements, requests, notices or agreements shall take effect upon receipt thereof.
26
14. This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and the Selling Stockholders and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company, any Selling Stockholder or any Underwriter, or any director, officer, employee, or affiliate of any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such purchase.
15. Time shall be of the essence of this Agreement. As used herein, the term “business day” shall mean any day when the Commission’s office in Washington, D.C. is open for business.
16. (a) The Company and the Selling Stockholders acknowledge and agree that (i) the purchase and sale of the Shares pursuant to this Agreement is an arm’s length commercial transaction between the Company and the Selling Stockholders, on the one hand, and the several Underwriters, on the other, (ii) in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company or any Selling Stockholder, (iii) no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company or any Selling Stockholder with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any Selling Stockholder on other matters) or any other obligation to the Company or any Selling Stockholder except the obligations expressly set forth in this Agreement, and (iv) the Company and each Selling Stockholder has consulted its own legal and financial advisors to the extent it deemed appropriate. The Company and each Selling Stockholder agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company or any Selling Stockholder, in connection with such transaction or the process leading thereto.
(b) The Company and each Selling Stockholder acknowledge that in connection with the offering of the Shares, none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company and each Selling Stockholder waive to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares.
(c) Each Selling Stockholder further acknowledges and agrees that, although the Underwriters may provide certain Selling Stockholders with certain Regulation Best Interest and Form CRS disclosures or other related documentation in connection with the offering, the Underwriters are not making a recommendation to any Selling Stockholder to participate in the offering or sell any Shares at the purchase price set forth in Section 2 herein, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation.
17. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company, the Selling Stockholders and the Underwriters, or any of them, with respect to the subject matter hereof.
27
18. This Agreement and any transaction contemplated by this Agreement and any claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would result in the application of any other law than the laws of the State of New York. The Company and each Selling Stockholder agree that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company and each Selling Stockholder agree to submit to the jurisdiction of, and to venue in, such courts.
19. The Company, each Selling Stockholder and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
20. This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
21. Notwithstanding anything herein to the contrary, the Company and the Selling Stockholders are authorized to disclose to any persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company and the Selling Stockholders relating to that treatment and structure, without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, “tax structure” is limited to any facts that may be relevant to that treatment.
22. Recognition of the U.S. Special Resolution Regimes.
(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
28
(c) As used in this section:
“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).
“Covered Entity” means any of the following:
(i) (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii) (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
(iv) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
(v) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
[remainder of page intentionally left blank]
29
If the foregoing is in accordance with your understanding, please sign and return to us one for the Company and each of the Representatives plus one for each counsel and the Custodian counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement among each of the Underwriters, the Company and each of the Selling Stockholders. It is understood that your acceptance of this Agreement on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company and the Selling Stockholders for examination, upon request, but without warranty on your part as to the authority of the signers thereof.
Any person executing and delivering this Agreement as Attorney-in-Fact for a Selling Stockholder represents by so doing that he has been duly appointed as Attorney-in-Fact by such Selling Stockholder pursuant to a validly existing and binding Power-of-Attorney that authorizes such Attorney-in-Fact to take such action.
| Very truly yours, | ||
| FIGS, INC. | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page to Underwriting Agreement]
| TULCO, LLC | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page to Underwriting Agreement]
|
HEATHER HASSON |
[Signature Page to Underwriting Agreement]
|
CATHERINE SPEAR, TRUSTEE OF THE CATHERINE SPEAR REVOCABLE TRUST U/A/D 12/18/2017 |
[Signature Page to Underwriting Agreement]
| Accepted as of the date hereof | ||
| GOLDMAN SACHS & CO. LLC | ||
| By: | ||
| Name: | ||
| Title: | ||
| MORGAN STANLEY & CO. LLC | ||
| By: | ||
| Name: | ||
| Title: | ||
| On behalf of each of the Underwriters | ||
[Signature Page to Underwriting Agreement]
SCHEDULE I
| Underwriter |
Total Number of Firm Shares to be Purchased |
Number of Optional Shares to be Purchased if Maximum Option Exercised |
||||||
| Goldman Sachs & Co. LLC |
[ | •] | [ | •] | ||||
| Morgan Stanley & Co. LLC |
[ | •] | [ | •] | ||||
| Barclays Capital Inc. |
[ | •] | [ | •] | ||||
| Credit Suisse Securities (USA) LLC |
[ | •] | [ | •] | ||||
| BofA Securities, Inc. |
[ | •] | [ | •] | ||||
| Cowen and Company, LLC |
[ | •] | [ | •] | ||||
| Guggenheim Securities, LLC |
[ | •] | [ | •] | ||||
| KeyBanc Capital Markets Inc. |
[ | •] | [ | •] | ||||
| Piper Sandler & Co. |
[ | •] | [ | •] | ||||
| Oppenheimer & Co. Inc. |
[ | •] | [ | •] | ||||
| Telsey Advisory Group LLC |
[ | •] | [ | •] | ||||
| Academy Securities, Inc. |
[ | •] | [ | •] | ||||
| R. Seelaus & Co., LLC |
[ | •] | [ | •] | ||||
| Samuel A. Ramirez & Company, Inc. |
[ | •] | [ | •] | ||||
| Siebert Williams Shank & Co., LLC |
[ | •] | [ | •] | ||||
|
|
|
|
|
|||||
| Total |
[ | •] | [ | •] | ||||
I-1
SCHEDULE II
| Underwriter |
Total Number of Firm Shares to be Sold |
Number of Optional Shares to be Sold if Maximum Option Exercised |
||||||
| The Selling Stockholder(s): |
||||||||
| Tulco, LLC(a) |
[ | •] | [ | •] | ||||
| Management Selling Stockholders: |
||||||||
| Heather Hasson(b) |
[ | •] | [ | •] | ||||
| Catherine Spear Revocable Trust U/A/D 12/18/2017(b) |
[ | •] | [ | •] | ||||
|
|
|
|
|
|||||
| Total |
[ | •] | [ | •] | ||||
| (a) | This Selling Stockholder is represented by Skadden, Arps, Slate, Meagher & Flom LLP, 525 University Ave., Palo Alto, CA 94301, Attention: Gregg Noel, Esq. |
| (b) | This Selling Stockholder is represented by Wilson Sonsini Goodrich & Rosati, P.C., 633 West Fifth Street, Suite 1550, Los Angeles, CA 90071-2027, Attention: Katherine (Kathy) H. Ku and David S. Thomas. |
II-1
SCHEDULE III
| (a) | Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package |
Electronic Roadshow dated September 2021
| (b) | Additional documents incorporated by reference |
None.
| (c) | Information other than the Pricing Prospectus that comprise the Pricing Disclosure Package |
The public offering price per share for the Shares is $[•].
The number of Shares purchased by the Underwriters is [•].
| (d) | Written Testing-the-Waters Communications |
[None.]
III-1
ANNEX I
FIGS, INC.
[FORM OF] LOCK-UP AGREEMENT
, 2021
Goldman Sachs & Co. LLC
Morgan Stanley & Co. LLC
As representatives of the several Underwriters
named in Schedule I to the Underwriting Agreement
| c/o | Goldman Sachs & Co. LLC |
200 West Street
New York, NY 10282
| c/o | Morgan Stanley & Co. LLC |
1585 Broadway
New York, NY 10036
| Re: | FIGS, Inc. – Lock-Up Agreement |
Ladies and Gentlemen:
The undersigned understands that you, as representatives (the “Representatives”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule I to the Underwriting Agreement (collectively, the “Underwriters”), with FIGS, Inc., a Delaware corporation (the “Company”), providing for a public offering (the “Public Offering”) of shares of Class A Common Stock of the Company (the “Shares”) pursuant to a Registration Statement (the “Registration Statement”) on Form S-1 to be filed with the Securities and Exchange Commission (the “SEC”).
Reference is made to the following facts:
| (A) | That the undersigned and the Representatives entered into that certain lock-up agreement (the “IPO Lock-up Agreement”) in connection with the Company’s initial public offering of Class A Common Stock (the “IPO”), relating to shares of Class A Common Stock or Class B Common Stock of the Company (collectively, “Common Stock”) and any options or warrants to purchase any shares of Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company (such options, warrants or other securities, collectively, “Derivative Instruments”), including without limitation any such shares of Common Stock or Derivative Instruments then owned or thereafter acquired by the undersigned; |
| (B) | That, pursuant to the terms of the fifth paragraph of the IPO Lock-Up Agreement (the “Early Release Provision”), a number of shares of Common Stock were released therefrom on August 27, 2021; and |
| (C) | That the IPO Lock-up Agreement shall terminate on the date that is the earlier of (i) November 22, 2021 and (ii) the second full Trading Day following the Company’s second public release of quarterly or annual financial results following the completion of its IPO (the “IPO Lock-up Termination Date”). |
II-1
In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning on the date of this agreement (this “Lock-Up Agreement”) and continuing to and including the IPO Lock-up Termination Date (the “Lock-Up Period”), the undersigned shall not, and shall not cause or direct any of its affiliates to, (i) offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of Common Stock or Derivative Instruments owned by the undersigned as of the date hereof and which are no longer subject to the IPO Lock-up Agreement pursuant to the Early Release Provision (the “Early Release Securities”), (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined), which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any Early Release Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a “Transfer”), or (iii) otherwise publicly announce any intention to engage in or cause any action or activity described in clause (i) above or transaction or arrangement described in clause (ii) above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to lead to or result in any Transfer during the Lock-Up Period.
If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or “group” (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a natural person, entity or “group” (as described above) that has executed a Lock-Up Agreement in substantially the same form as this Lock-Up Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.
Notwithstanding the foregoing, the undersigned may:
(a) transfer the undersigned’s Early Release Securities:
(i) as a bona fide gift or gifts or charitable contribution, or for bona fide estate planning purposes; provided that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein;
(ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein;
(iii) in connection with the sale or other Transfer of the undersigned’s shares of Common Stock of the Company acquired in open market transactions after the completion of the Public Offering;
II-2
(iv) upon death or by will or intestacy, provided that the legatee, heir or other transferee, as the case may be, agrees to be bound in writing by the restrictions set forth herein;
(v) to any immediate family member, provided that such immediate family member agrees to be bound by the restrictions set forth herein;
(vi) to a partnership, limited liability company or other entity of which the undersigned and the immediate family members of the undersigned are the legal and beneficial owners of all of the outstanding equity securities or similar interests, provided that the transferee agrees to be bound in writing by the restrictions set forth herein;
(vii) by operation of law or pursuant to a qualified domestic order or in connection with a divorce settlement or any related court order, provided that the transferee agrees to be bound in writing by the restrictions on transfer set forth herein;
(viii) as part of a distribution, transfer or disposition without consideration by the undersigned to its limited or general partners, members or equity holders, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or management with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), provided that the transferees agree to be bound in writing by the restrictions set forth herein;
(ix) pursuant to a bona fide third-party merger, consolidation, tender offer or other similar transaction involving a Change of Control (as defined below)) of the Company occurring after the settlement of the Public Offering that is approved by the Company’s board of directors and made to all holders of the Company’s capital stock, provided that all of the undersigned’s Early Release Securities subject to this Lock-Up that are not so transferred, tendered or otherwise disposed of remain subject to this Lock-Up Agreement; and provided further that, in the event that such Change of Control is not completed, the undersigned’s Early Release Securities shall remain subject to the restrictions contained in this Lock-Up Agreement and title to the undersigned’s Early Release Securities shall remain with the undersigned;
(x) to the Company pursuant to contractual arrangements under which the Company has, in connection with the termination of service of the undersigned, (A) the option to repurchase such Early Release Securities or (B) a right of first refusal with respect to transfers of such Early Release Securities; provided that in the case of clauses (A) and (B) above, (1) such contractual arrangement (or a form thereof) is described in the final prospectus related to the Public Offering (the “Prospectus”) or filed as an exhibit to the Registration Statement and (2) such contractual arrangement is in effect on the date of the Prospectus;
(xi) to the Underwriters pursuant to the Underwriting Agreement;
(xii) in connection with the vesting or settlement of restricted stock units or the exercise of options or other rights to purchase the shares of Common Stock (including, in each case, by way of “net” or “cashless” exercise), including (A) any transfer to the Company for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options or rights, and (B) any transfer of shares of Common Stock necessary to generate such amount of cash needed for the payment of withholding taxes due as a result of the vesting or settlement of restricted stock units or the exercise of options or other rights to purchase shares of Common Stock, in all such cases, pursuant to equity awards granted under a stock incentive plan or other equity award plan, which plan is described in the Prospectus; or
II-3
(xiii) with the prior written consent of Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC on behalf of the Underwriters; and
(b) enter into a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act relating to the transfer, sale or other disposition of securities of the undersigned, if then permitted by the Company; provided that the securities subject to the plan may not be sold during the Lock-Up Period (except to the extent otherwise allowed pursuant to clause (a) above) and no public announcement or filing under the Exchange Act, or any other public filing or announcement, shall be required or shall be voluntarily made regarding the establishment of such plan during the Lock-Up Period.
Notwithstanding anything to the contrary, in the case of clauses (i) through (iii), (v), (vi), (viii) and (x)(B) above, no filing under the Exchange Act or any other public filing or disclosure reporting a reduction in beneficial ownership of Early Release Securities by or on behalf of the undersigned shall be required or voluntarily made during the Lock-Up Period; in the case of any transfers pursuant to clauses (iv), (vii), (x)(A) and (xii) above, any filing that is required under the Exchange Act to be made during the Lock-Up Period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in such clauses; and in the case of any transfers pursuant to clauses (ii), (iv) and (v), any such transfer shall not involve a disposition for value.
For purposes of this Lock-Up Agreement, (i) “immediate family” shall mean any relationship by blood, marriage, domestic partnership or adoption, not more remote than first cousin, (ii) a “Trading Day” is a day on which the New York Stock Exchange is open for the buying and selling of securities and (iii) a “Change of Control” shall mean the transfer (whether by bona fide tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a “person” (as defined in Section 13(d)(3) of the Exchange Act) or group of affiliated persons (other than the Company), of the Company’s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting power of the voting share capital of the Company (or the surviving entity).
The undersigned agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s Early Release Securities except in compliance with the foregoing restrictions.
The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this Lock-Up Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect to this Lock-Up Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Public Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any shares at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation.
II-4
This Lock-Up Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
Notwithstanding anything to the contrary contained herein, this Lock-Up Agreement (and the Lock-Up Period described herein) will automatically terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreement, the Company advises the Representatives in writing that it has determined not to proceed with the Public Offering, (ii) the Company files an application to withdraw the Registration Statement, (iii) the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the Shares to be sold thereunder, or (iv) September 30, 2021, in the event that the Underwriting Agreement has not been executed by such date.
This Lock-Up Agreement shall be governed by and construed in accordance with the laws of the State of New York.
[Signature Page Follows]
II-5
The undersigned understands that the Company and the Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns.
| Very truly yours, | ||
|
| ||
| Name of Security Holder (Print exact name) | ||
| By: |
| |
| Signature | ||
| If not signing in an individual capacity: | ||
|
| ||
| Name of Authorized Signatory (Print) | ||
|
| ||
| Title of Authorized Signatory (Print) | ||
| (indicate capacity of person signing if signing as custodian, trustee or on behalf of an entity) | ||
[Signature Page to FIGS, Inc. Lock-Up Agreement]
II-6
Exhibit 5.1
|
|
1271 Avenue of the Americas New York, New York 10020-1401 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com
FIRM / AFFILIATE OFFICES | |||
| Beijing | Moscow | |||
| Boston | Munich | |||
| Brussels | New York | |||
| Century City | Orange County | |||
| Chicago | Paris | |||
| Dubai | Riyadh | |||
| September 13, 2021 | Düsseldorf | San Diego | ||
| Frankfurt | San Francisco | |||
| Hamburg | Seoul | |||
| Hong Kong | Shanghai | |||
| Houston | Silicon Valley | |||
| London | Singapore | |||
| Los Angeles | Tokyo | |||
| Madrid | Washington, D.C. | |||
| Milan | ||||
FIGS, Inc.
2834 Colorado Avenue, Suite 100
Santa Monica, California 90404
| Re: | Registration Statement on Form S-1 |
Up to 10,150,708 shares of Class A common stock of FIGS, Inc.
Ladies and Gentlemen:
We have acted as special counsel to FIGS, Inc., a Delaware corporation (the “Company”), in connection with the proposed registration of up to 10,150,708 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), to be sold by the selling stockholders (including up to 1,324,005 shares of Common Stock issuable upon exercise of the underwriters’ option to purchase additional shares from the selling stockholders). The Shares are included in a registration statement on Form S-1 under the Securities Act of 1933, as amended (the “Act”), initially filed with the Securities and Exchange Commission (the “Commission”) on September 13, 2021 (as amended, the “Registration Statement”). The term “Shares” shall include any additional shares of common stock registered by the Company pursuant to Rule 462(b) under the Act in connection with the offering contemplated by the Registration Statement. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws.
September 13, 2021
Page 2
Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, the Shares have been duly authorized by all necessary corporate action of the Company and are validly issued, fully paid and non-assessable.
This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under the heading “Legal Matters.” We further consent to the incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule 462(b) with respect to the Shares. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
| Very truly yours, |
| /s/ LATHAM & WATKINS LLP |
Exhibit 23.1
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 17, 2021, except for the effects of the stock split discussed in Note 2 to the financial statements, as to which the date is May 20, 2021, in the Registration Statement (Form S-1) and related Prospectus of FIGS, Inc. for the registration of shares of its Class A common stock.
| /s/ Ernst & Young LLP |
Los Angeles, California
September 13, 2021
Exhibit 23.3
| FIGS, Inc. |
September 13, 2021 |
2834 Colorado Avenue, Suite 100
Santa Monica, CA 90404
Dear FIGS, Inc.:
We, Frost & Sullivan of 3211 Scott Blvd, #203, Santa Clara, California, 95054, hereby consent to the filing with the Securities and Exchange Commission of a Registration Statement on Form S-1, and any amendments thereto (the “Registration Statement”) of FIGS, Inc., and any related prospectuses of (i) our name and all references thereto, and (ii) the statements set out in the Schedule hereto. We also hereby consent to the filing of this letter as an exhibit to the Registration Statement.
We further consent to the reference to our firm, under the caption “Industry and Market Data” in the Registration Statement, as acting in the capacity of an author of independent industry publications.
Yours faithfully,
/s/ Debbie Wong
Name: Debbie Wong
Designation: Vice President
For and on behalf of Frost & Sullivan
SCHEDULE
| 1. | In 2020, the total addressable market of the healthcare apparel industry was an estimated $12.0 billion in the United States and $79.0 billion globally, according to an April 2021 Frost & Sullivan study that we commissioned. |
| 2. | Supported by these key trends, the healthcare apparel industry is expected to demonstrate strong and consistent growth, with the total addressable market in the United States expected to grow by a 6.1% CAGR over the next five years, from approximately $12.0 billion in 2020 to approximately $16.0 billion in 2025, according to the Frost & Sullivan study. |
| 3. | In 2020, the total addressable market of the U.S. healthcare apparel industry was approximately $12.0 billion, according to the Frost & Sullivan study. |
| 4. | Among U.S. healthcare professionals and medical students, we have aided and unaided brand awareness of 55% and 22%, respectively, according to a survey performed by Frost & Sullivan. |
| 5. | According to the Frost & Sullivan study, the number of healthcare professionals and medical students internationally is expected to grow from approximately 118 million in 2020 to an estimated 124 million in 2025, and the total addressable market for international healthcare apparel is expected to grow from an estimated $67.0 billion in 2020 to an estimated $86.0 billion in 2025. |
| 6. | Certain information in this prospectus is based on the following research study, which we commissioned: Frost & Sullivan, US and Global Total Addressable Market (TAM) Assessment for the Medical Apparel Market, April 2021. The Frost & Sullivan study included a quantitative and qualitative analysis of the industry through primary and secondary research, including a quantitative survey, encompassing 200 respondents in the United States, all of whom were either professionals or medical students over the age of 18, wear scrubs to work or at school and own or have purchased at least one set of scrubs in the past 12 months. The Frost & Sullivan study calculated the U.S. and global total addressable markets for the healthcare apparel industry by identifying the total number of individuals in the engaged population (which is defined as healthcare professionals and medical students) and multiplying that number by the estimated average spend of the engaged population on medical apparel (based on data aggregated from the survey study). |